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Abstract 
We have developed a simple and efficient synthetic route, starting from easily available 
starting materials, to the novel ring system benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide. 
A series of chalcones were synthesized which were subsequently reacted with 
chlorosulphonic acid to generate the chalcone sulphonyl chlorides. The chalcone sulphonyl 
chlorides were then treated with bromine to generate the dibromo chalcone sulphonyl 
chlorides. These were subsequently reacted with 1,2-diaminopropane and 2-methyl-1,2-
diaminopropane in boiling ethanol resulting in compounds 22-30 and 31-39 respectively, in 
12-80% yields. The products were recrystallized using appropriate solvents and were 
characterized by spectral analysis, melting point, infrared spectroscopy, 1H and 13C NMR and 
mass spectrometry. In addition to spectral analysis, X-ray crystallography data was also 
collected for compound 31, confirming the definitive structure of the synthesized 
compounds. 
The reaction is believed to occur by the domino effect. The less sterically hindered amino 
group reacts with the sulphonyl chloride group to from the sulphonamide. The 
sulphonamide group then reacts with the β-carbon by nucleophilic substitution to form the 
isothiazole ring system and then the second amino group reacts with the α-carbon with 
elimination of the bromide ion to form the pyrazine ring. X-Ray data confirmed the structure 
of compound 31 and clearly confirmed that the dimethyl groups were on the carbon atom 
adjacent to the NH group. The synthesized compounds have been screened for potential 
antimicrobial properties against Bacillus subtilis, Escherichia coli, Proteus hauseri and 
Staphylococcus aureus.   
Compound 27 displayed antibacterial activity against B. subtilis at a concentration of 416 
µgml-1. Compounds 23, 24, 25, 26, 34, 35 and 36 all showed activity against B. subtilis at a 
concentration of 6.67 mg ml-1, generally the compounds synthesized displayed activity at 
the highest concentration and were more active against gram positive bacteria.  
A simple, efficient method for the synthesis of the novel benzo[4,5]isothiazolo[2,3-
a]pyrazine-6,6-dioxide ring system which should be applicable to generate other fused 
pyrazine ring systems of biological interest has been developed.  
 
Keywords: benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide, dibromochalcone sulphonyl, 
antibacterial and  antifungal 
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Chapter 1 
1.1 Introduction 
Bacterial infections and diseases have been responsible for the disruption of populations for 
thousands of years; this includes fatalities of humans, livestock, plants and crops. Noted 
throughout history, epidemics of certain diseases have successfully wiped out entire 
communities ranging from hundreds to millions of deaths. Advances in science and 
technology have provided the medical world with the information required to eradicate 
many deadly diseases from re-emerging. 
Through the development of vaccines and a better understanding hygiene, most developed 
countries have managed to maintain a strong hold at keeping fatal and highly infectious 
disease to a bare minimum. From the discovery of penicillin in the beginning of the 20th 
century there has been an astronomical breakthrough in the variety and quantity of 
different antibiotics available which gave way to the “golden age” of antibiotics.  
Antibacterial resistance has provoked an urgent need for novel antimicrobial compounds. 
There has been a significant decline in the number of new antibacterial agents being 
released onto the market, with as few as five new drugs being successfully developed in a 
four year period (Moellering, 2011). 
Research by the Infectious Disease Society of America has stated that there needs to be a 
minimum of ten new antimicrobial agents developed within the next eight years (Policy, 
2010). The interest in antibacterial development has become less intense due to major 
pharmaceutical companies focusing their R&D into more profitable drugs, such as 
anticancer and drugs for neurological diseases. According to Theueretzbacher the 
development of antibacterial agents has slowed considerably, the main research in 
developing these group of drugs is being carried out in academic institutions 
(Theuretzbacher, 2009). A possible reason for this could be that there are very few targets 
available for selective toxic agents to act at. The expected success of High-through put 
screening and combinatorial libraries did not live up to the expectations et al, 2007). The 
development of antimicrobial resistance has generated a huge demand for successful 
production of novel pharmaceutically active compounds. 
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1.2 Antibacterial agents 
The success of antibacterial agents is due largely to the fact that they can act selectively 
against the bacterial cell instead of the mammalian cell. Antibacterial agents have been 
reported throughout history for many centuries, elements of both ancient Chinese and 
Ayurvedic are still found in modern medicine (Singh & Barrett, 2006). The discovery of 
penicillin in 1928 was the beginning of the antibiotic “golden age” and for the next two 
decades many new antibacterial agent were developed (Saga & Yamaguchi, 2009). In half a 
century the available antibiotics increased 10 fold with the arrival of sulphonamides, 
streptomycin, tetracyclines, cephalosporins (Overbye & Barrett, 2005) and quinolone based 
antibiotics. The number of antibacterial agents available today covered a wide variety of 
bacterial diseases.  
 
1.3 Antibacterial agents: mechanism of action 
The structure, biochemistry and metabolism of a bacterial cell differs greatly to an animal 
cell, which enables a variety of ways an antibiotic can actively exert a therapeutic effect. The 
main mechanisms in which antibacterial agents work are commonly categorized into the 
following groups.  
 Disruption of cell wall synthesis these include β-lactam antibiotics, vancomycin and 
cephalosporins. The bacterial cell wall is encased in layers of peptidoglycan which is 
a complex matrix consisting of amino sugar chains cross linked via peptide bonds. β-
lactam antibiotics work by inhibiting the cross linking of peptidoglycan by inhibition 
of peptide bond formation, whereas vancomycin binds to the sugar component of 
peptidoglycan and prevents the synthesis of the glycan backbone (Tenover, 2006). 
 Inhibition of protein synthesis these include tetracyclines and aminoglycosides. 
Bacterial ribosomes are responsible for protein synthesis and comprise of two 
ribonucleoprotein subunits, 50S and 30S. 50S ribosome inhibitors (macrolides) work 
by prevention of the initiation phase of mRNA translation whereas the 30S ribsome 
inhibitors (tetracyclines) work by inhibiting the association of aminoacyl tRNA to the 
bacterial ribosome (Chopra & Roberts, 2001). 
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 Metabolic pathway disruption, sulphonamides work by interfering with the synthesis 
of folate which is essential in the synthesis of bacterial DNA precursors. Bacterium 
use p-aminobenzoic acid to synthesise folate, using the enzyme dihydropteroate 
synthetase, sulphonamides competitively inhibit this enzyme and therefore stop 
bacterial DNA replication (Boufas et al, 2014). 
 Nucleic acid synthesis inhibitors can be further divided into DNA or RNA synthesis 
inhibitors. The drug rifampicin inhibits nucleic acid production by binding next to the 
active site on the RNA polymerase enzyme and blocking the RNA elongation step. 
Quinolone antibiotics are DNA synthesis inhibitors which inhibit the enzyme 
topoisomerase, this enzyme is responsible for the winding and unwinding of the 
double helix that is required for replication. (Aggarwal, Kumar, Dureja, & Khurana, 
2011). 
 Disruption of the bacterial cell membrane which is achieved by interfering with the 
integrity of the cell membrane, and results in bacterial cell death. The drug 
polymyxin disrupts the bacterial cell wall due to the binding of the drug and the 
lipopolysaccharides (LPS) on the outer membrane. The binding of the drug to the LPS 
causes both inner and outer membranes to disintegrate (Falagas, Rafailidis & 
Mattaiou, 2010). 
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Mode of action Example of antibacterial agent 
Interference with cell wall synthesis beta-Lactams: penicillins, cephalosporins, 
carbapenems, monobactams,  
Glycopeptides: vancomycin, teicoplanin 
 
Protein synthesis inhibition Bind to 50S ribosomal subunit -macrolides, 
chloramphenicol, clindamycin, quinupristin-
dalfopristin and linezolid 
 
Bind to 30S ribosomal subunit – aminoglycosides 
and  tetracyclines 
Interference with nucleic acid synthesis Inhibit DNA synthesis: ﬂuoroquinolones 
Inhibit RNA synthesis: rifampin 
Inhibition of metabolic pathway Sulphonamides and folic acid analogues 
Disruption of bacterial membrane structure polymyxins and daptomycin 
Table 1: a summary of the different types of antibiotics based on mode of action (Tenover’ 
2006) 
 
1.4 Antimicrobial resistance 
Due to the emergence of superbugs such as methicillin resistant Staphylococcus aureus 
(MRSA), many antibiotics are no longer effective therapeutic agents. Although MRSA and 
vancomycin resistance appears to be stabilising (Paphitou, 2013) there are new problems 
occurring. Gonorrhoea is the latest medical condition that has developed a resistance to a 
wide range of antibiotics with only third generation cephalosporins being effective (Ndowa 
& Lusti-Narasimhan, 2012).  
Drug resistant tuberculosis, multidrug resistant tuberculosis (MDR-TB) and extensively drug 
resistant tuberculosis (XDR-TB) is becoming increasingly difficult to treat. Drugs such as 
rifampicin and isoniazid were once freely administered but have recently proved ineffective. 
Although the global prevalence of TB has seen a decline an estimated nine million new cases 
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of TB were reported in 2011 (Santos, Pires, Azeredo Bittencourt, Tufik, & Andersen, 2012). 
With this ancient infectious disease still claiming millions of lives each year there is a 
desperate need to develop novel and potent anti-TB drugs. 
Current trends have indicated a significant rise in the number of gram negative pathogens 
developing resistance. Over the last decade E. coli and Klebsiella pneumoniae have displayed 
that third generation cephalosporins and combination therapies that include 
aminopenicillins, fluouroquinolones and aminoglycosides are no longer effective (Paphitou, 
2013).  
The latest research into antimicrobial resistance has stated that multidrug resistant 
pathogens are spreading at an unprecedented rate. Whilst many gram-positive organisms 
such as Staphylococcus aureus and Enterococcus species can be treated with a limited 
number of drugs whereas gram-negative bacteria have developed resistance to almost all 
prescribed antibiotics (Theuretzbacher, 2013).  
The efficacy of any therapeutic agent becomes limited by the potential risk of resistance. 
From the late 1920’s up until the late 1990’s the expansion in the number and variety of 
antibacterial agents  available had increased exponentially however the last decade has 
seen a decrease in the emergence of novel antibacterial agents. With fewer new 
antibacterial agents being designed and produced coupled with the increase in antibacterial 
resistance there has been a significant increase in nosocomial infections and other new fatal 
medical implications that have reduced the variety of drugs available for prescription.  
Figure 1 gives a brief outline of the history of antibacterial agents and antibacterial 
resistance. 
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Figure 1: outlines the history of antibacterial agents, and the emergence of antibacterial 
resistance (Saga & Yamaguchi, 2009). 
Although there is much interest in the combination of cephalosporins to a new β-lactamase 
inhibitor, this presents a challenge. β-Lactamase inhibitors are not effective for all                
β-lactamase related resistance. It was also stated that one of the only ways to get a 
stranglehold on emerging resistance is to develop a novel compound or chemical scaffold 
unrelated to known antimicrobial agents.  
 
 
 
 
 
 
 
13 
 
1.5 Antimicrobial resistance: Mechanism of action 
Antibacterial resistance is thought to be the result of overuse and misuse of antibiotics, 
(Paphitou, 2013) up until the 1970s most physicians believed that the majority of bacterial 
infections could be effectively treated by a wide variety of antibacterial agents. Antibiotics 
were widely prescribed and through this many strains of bacteria have evolved and have 
become resistant to a broad range of antibiotics. Some bacteria have acquired resistance to 
more than one line of antibiotics, which has paved way for the emergence of “superbugs”. 
Resistance can either be innate or acquired, innate resistance is naturally occurring in some 
bacterial species which renders antibiotics ineffective before the pathogen has been 
introduced to the drug (Ebrahim, 2010). Acquired resistance is mainly a result of genetic 
mutations, these mutations have enabled bacteria to develop a variety of mechanisms 
which prevent the efficacy of the antibiotics. 
Some bacteria have acquired resistance through genetic mutations; these mutations have 
enabled bacteria to develop a variety of mechanisms which render antibiotics useless. Some 
organisms have acquired efflux pumps that have the ability to remove the antibacterial 
agent before it reaches its target site, other mutations have evolved the bacterial cell wall 
so that the necessary antibiotic binding sites are present thus preventing the drug from 
entering the cell (Tenover, 2006). Research into the trends and patterns of antibacterial 
resistance has been extensively reported over the last three decades. Methicillen resistance 
Staphylococcus aureus (MRSA) has been monitored intensely and it has been reported that 
the rate of resistance for this bacterium has stabilised (Livermore, 2012). The main 
mechanism in resistance in MRSA involves target site alteration, through genetic mutations 
S. aureus has acquired penicillin binding proteins and an increase  -lactam antibiotic 
resistance (Appelbaum, 2007). 
Bacteria such E. coli and S. aureus have become more resistant via the emergence of β-
lactamases produced naturally by bacteria which destroy β-lactam antibiotics. Although 
these enzymes are found in bacteria through genetic mutation they have become more 
problematic by becoming extended broad spectrum β-lactamases (ESBL’s), with over 150 
ESBLs being described (Bradford, 2001). 
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Another mechanism of acquired antimicrobial resistance is horizontal gene transfer (HGT), 
this is where genetic information coding for resistance for one type of bacteria is laterally 
transferred to another species of bacteria. This transfer of genetic material is possible 
through the mobility of some genetic elements such as plasmids, gene cassettes, 
transposons and bacteriophages (Cruz & Davies 2000). Horizontal gene transfer has several 
mechanisms and is thought to be one of the main contributing factors of antibiotic 
resistance. Bacterial HGT mainly occurs through transformation of DNA this is where 
bacterial cells uptake fragments of naked DNA.  Transduction is another mechanism in 
which genetic material is passed from one cell to another and is done so via a bacteriophage 
which is a virus that can infect and replicate with a bacterial cell. Plasmids like 
bacteriophages act as vehicles for HGT, plasmids can pass genetic material via cell to cell 
contact almost creating a corridor type system where DNA can pass easily from cells 
(Lindsey, 2014). 
 This has been observed in Staphylococcus species where vancomycin resistance S. aureus 
have acquired the genes that code for vancomycin resistance from Enterococci species. The 
ability bacteria have to spread antibiotic resistant genes across species has contributed 
greatly to struggle in combating antimicrobial resistance (Sung & Lindsay, 2007). The actual 
mechanism of vancomycin resistance in S. aureus is yet to be fully elucidated (Srinivasan, 
Dick & Perl 2002). 
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Figure 2: A table to show what mechanisms have been developed by bacteria to combat 
certain types of antibiotics (Davies & Davies 2010). 
 
 
Antibiotic class Target Mode(s)of resistance  
Β-Lactams Peptidoglycan 
biosynthesis 
Hydrolysis, efflux, altered target 
Aminoglycosides Translation Phosphorylation, acetylation, nucelotidylation, efflux, 
altered target 
Glycopeptides Peptidoglycan 
biosynthesis 
Repogramming peptidoglycan biosynthesis 
Tetracyclines Translation  Monooxygenation, efflux, altered target 
Macrolides Translation Hydrolysis, glycosylation, phosphorylation, efflux, 
altered target 
Lincosamides Translation Nucletotidylation, efflux, altered target 
Streptogramins Translation C-O lyase (type B streptogramins),  
Acetylation (type A streptogramins), efflux, altered 
target  
Oxazolidinones Translation Efflux, altered target 
Phenicols Translation Acetylation, efflux, altered target  
Quinolones DNA replication  Acetylation, efflux, altered target 
Pyrimidines C1 metabolism  Efflux, altered target 
Sulfonamides C1 metabolism Efflux, altered target 
Rifamycins Transcription  ADP-ribosylation, efflux, altered target 
Lipopeptides Cell membrane Altered target 
Cationic 
peptides  
Cell membrane Altered target, efflux 
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1.6 Antifungal agents 
Antifungal agents are most easily divided into two categories natural products such as 
polyenes and echinocandins and synthetic drugs such as the azoles and pyrimidines (Odds, 
2003). Fungi are eukaryotic as are humans, so when developing anti-fungal agents it is 
essential to ensure that the agents to not cause harm to the human host (Thompson, 
Cadena, & Patterson, 2009), which also this limits the sites of action where antifungal agents 
can act. 
The first antifungal agent in use was griseofulvin 1 in 1939 (Sheehan, Hitchcock, & Carol, 
1999) which was the first basic dermal antifungal. This gave way to the azole and polyene 
antifungal groups. In the 1950s Amphotericin B (Amp B a polyene) isolated from 
Streptomyces nodosusand was discovered and found to be a very effective antifungal in 
systemic mycosis and is still the gold standard in systemic fungal infections. However Amp B 
is poorly soluble and is notoriously nephrotoxic (Kleinberg, 2006).  To reduce the toxicity of 
Amp B, lipid based formulations were designed to protect the kidneys. In recent years Amp 
B has been used in combination with other antifungals to reduce the nephrotoxicity of the 
drug (Barrett et al., 2003). The last 70 years has given rise to numerous novel antifungal 
agents however azoles are still the most widely used (Odds, 2003). Through understanding 
of the fungal cell (genome, cell wall and cell membrane) there has been a rapid advance of 
more effective and less toxic antifungals (Smith & Kauffman, 2012). For the past decade the 
azole class of antifungals have become the most commonly used and prescribed, however 
the overuse of this group has lead to increased resistance and poor efficacy (Chai et al., 
2011). Ketoconazole 2 is still widely used and is commonly found in many antidandruff 
shampoos and is used as a starting point for novel azole derivatives (Oh, Yamada, Asami, & 
Yoshizawa, 2012). 
This has sparked a new area of interest into the azole scaffold; the need for novel antifungal 
agents has become increasingly important with new emerging fungal pathogens coupled 
with the increase of antifungal resistance. 
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                          1                      2 
Figure 3: show the structures of griseofulvin 1 and ketoconazole 2 (Kahsay, Olajire, 
Schepdael, & Adams, 2013). 
 
1.7 Antifungals: Mechanism of action 
The fundamental difference between fungal cells and mammalian cells is the sterol 
molecule present in fungi, ergosterol, which is found in the fungal cell membrane. 
Ergosterol carries out the same functions as cholesterol. Like antibacterial agents, antifungal 
agents have many mechanisms by which they are effective. 
Fungal ergosterol synthesis inhibitors such as  azoles inhibits the conversion of lanosterol to 
ergosterol by targeting the enzyme lanosterol 14α-demethylase (Ahmad, Khan, Manzoor, & 
Khan, 2010). Squalene epoxidase inhibitors include terbinafin, which inhibit the production 
of lanosterol, which consequently inhibits the synthesis of ergosterol. Ergosterol distruptors  
like polyenes bind to ergosterol, creating pores in the cell membrane which causes an efflux 
of cellular potassium, which ultimately results in cell lysis (Kanafani & Perfect, 2008). Glucan 
synthesis inhibitors such as the drug class echinocandins inhibit the synthesis of β-glucan 
which is essential in the fungal cell wall. Chitin synthase inhibitors, chitin plays an important 
role in maintaining fungal cell wall integrity, inhibition of this glucose derivative will lead to 
fungal cell impairment and ultimately cell death. Other mechanisms of action include 
nucleic acid synthesis inhibitors, protein synthesis inhibitors and microtubule synthesis 
inhibitors. 
From the literature available the most recent research into novel antifungal agents is based 
on developing and synthesizing analogs of known biologically active scaffolds. Compounds 
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being investigated include benztriazoles 3, benzimdazoles 4 and quinolones 5 (see figure 3) 
pyrazines and thiophenes (Kathiravan et al., 2012).  
 
   3                4        5  
Figure 4: shows chemical structure for benztriazoles 3, benzimidazoles 4 and quinolone 5. 
 
1.8 Antifungal resistance 
Antifungal resistance is playing a significant role in the fight against invasive fungal 
infections and is becoming very problematic when treating immunocompromised patients 
(Kanafani & Perfect, 2008).  The understanding and emergence of antifungal resistance has 
lagged behind antibacterial resistance, this is thought to be due to recent advances in 
medicines which suppress the immune system (Ghannoum & Rice, 1999). Current 
antifungals such as azoles, polyenes and echinocandins are no longer as effective.  Azole 
resistance has been categorized into four mechanisms: decreased drug concentrations; 
target site alteration; up-regulation of target enzyme, and the development of bypass 
pathways (Kanafani & Perfect, 2008). Similar to bacterial cells, Candida fungal species have 
developed efflux pumps which decrease the amount of antifungal agent that reaches its 
target site. Resistance to polyenes and echinocandins have been reported but the 
mechanism in which antifungal resistance has emerged has yet to be elucidated (Kanafani & 
Perfect, 2008). 
Much research in the past decade has been centred on improving already known 
antimicrobial agents. The research presented in this thesis is based on taking two known 
heterocycles and combining them to synthesise a set of novel compounds which display 
important biological properties. 
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1.9 Antibiotic susceptibility methods 
The definition of antimicrobial resistance is predominantly defined using  minimal inhibitory 
concentration (MIC) breakpoints and a lot of research has been conducted into 
standardizing susceptibility testing methods to outline how antimicrobial resistance is 
defined (Ghannoum & Rice, 1999). Antibacterial susceptibility tests were standardized in the 
late 1970’s (Wheat, 2001); only recently have there been standardized and test guidelines 
for a limited number of fungal species published (Kanafani & Perfect, 2008).  
It is important to be able to determine the resistance of a bacterial isolate to a particular 
antibiotic to gain a better understanding of how resistance has come about. One of the 
earliest antibacterial susceptibility tests used is the broth dilution method. This method uses 
2 fold dilutions of an antibiotic in either tubes or a microtitre plate; to this a standardized 
inoculated bacterial suspension is added. The lowest concentration of antibiotic that 
prevents growth is the MIC. The MIC value can then be further investigated by further serial 
dilution of the MIC (Jorgensen & Ferraro, 2009). Disk diffusion is another method used to 
determine antimicrobial susceptibility; an appropriate agar plate is inoculated with either 
bacteria or fungi. Then a standard antibiotic disk or disks will be placed on the agar plate, 
after incubation the zone of inhibition around the antibiotic disk is measured. If there is a  
zone of inhibition a further test can be done by taking some of the agar from the zone of 
inhibition and placed on a sterile plate and left to incubate (Martos et al., 2012). If there is 
no further growth then it can be assumed that the antibiotic used in bactericidal, or if 
further growth is observed then it could be assumed that the antibiotic is bacteriostatic. 
 
1.10 The relevance of fusing heterocycles 
Heterocycles are an enormously diverse group of compounds that are widely distributed in 
nature, and are found in many pharmaceuticals. Heterocycles are easily manipulated in 
organic synthetic routes; the compounds can be easily modified to increase or decrease 
reactivity (Dua, Shrivastava, Sonwane, & Srivastava, 2011). Varying substituent groups (ring 
activators or deactivators) and their positions around the rings can result in novel libraries 
of biologically diverse heterocyclic compounds. Heterocycles are used extensively as 
intermediates in reactions and as building blocks too in synthesis. Incorporation and 
20 
 
substitution of a wide range of functional groups in heterocyclic systems provides an 
endless number of compounds. 
This also leads to synthetic chemists continuously striving for new, more selective synthetic 
methods to provide a wider range of heterocyclic derivatives; this includes the fusing of 
different heterocycles and varying functional groups in order to continuously produce novel 
heterocyclic compounds.  
Over the last few decades the study of medicinal chemistry has gone from strength to 
strength, the discovery and elucidation of the human genome, computational chemistry and 
the development of a variety of different biological assays have paved the way for research 
into novel compounds being synthesised and screened for biological importance. With the 
recent advent of antimicrobial resistance the area of medicinal chemistry has become even 
more essential in drug discovery.   
There is a continuing emergence of new drug resistant strains of a wide variety of bacterial, 
fungal and viral diseases with gold standard drugs no longer exerting effective activity. 
Although there is a plethora of medicines and vaccines available to treat and prevent most 
ailments, supply is no longer meeting demand and the need for novel biologically active 
compounds is increasing. Over the last decade there has been a reported increase in the 
rate of resistance in regards to gram negative pathogens (Paphitou, 2013). Methicillen 
resistance Staphylococcus aureus is still a key problem in trying to combat antibacterial 
resistance (Gould et al., 2012). 
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1.10.1 Benzoisothiazoles 
Benzoisothiazoles are heterocycles consisting of a benzene ring fused to an isothiazole ring. 
The first known benzoisothiazole derivative with known biological importance was    
saccharin 6. 
 
 
 
 
     
      6       7 
 
Figure 5: shows the chemical structure saccharin 6 and benzo[d]isothiazole 7.  
 
Saccharin 6 is five hundred times sweeter than sugar and has gained attention over the past 
century as an alternative to sugar (Sawant, 2011). Benzoisothiazole 8 rings are found in 
many chemically interesting compounds, these compounds and derivatives have been 
synthesized and have shown varied biological activity (Yadav & Senthilkumar, 2011). 
Chaudhary and co-workers (Chaudhary, Sharma, Sharma, & Varshney, 2010), stated that 
substituted benzoisothiazole compounds have antitumor, anti-allergic, anti-diabetic, anti-
inflammatory, anthelmintic and anti-HIV activity (Chaudhary, Sharma, Sharma, & Varshney, 
2010). 
Benzo[d]isothiazole-1,1-dioxide 8 derivatives have been screened for antimicrobial, antiviral 
and antiproliferative activity (Vicini et al., 2003).  
 
 
 
8 
Figure 6: shows the structure of a benzo[d]isothiazole-1,1-dioxide derivative 8. 
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Benzo[d]isothiazole combined with an arylidene moiety (a methylene derivative of an aryl 
group) with different substituent such as methyl groups and fluorine atoms, have displayed 
cytotoxicity against human CD4+ lymphocytes. These compounds inhibited the growth of 
leukaemia cell lines and also antiproliferative activity against solid tumour-derived cell lines 
(Vicini et al., 2003). Vicini and co-workers investigated benzoisothiazole hydrazone 
derivatives as possible antiviral (anti-HIV-1) agents. The investigation focused on the 
structural requirements that are essential for anti-HIV activity and how modifying the alkene 
chain length between the benzoisothiazole ring and the hydrazone group would increase or 
decrease any possible anti-HIV activity. Although many of the compounds did show 
promising results the mechanism of action remains to be elucidated (Vicini, Incerti, La Colla, 
& Loddo, 2009). Benzothiazole derivatives have also been found to inhibit human 
cyclooxygenase-2-enzymes (COX-2) (Paramashivappa, Phani Kumar, Subba Rao, & Srinivasa 
Rao, 2003). 
Recent research in CNS-mediated diseases has given rise to discovery of a family of 
serotonin (5-HT) receptors, 5-HT6. In vivo studies have shown that inhibition of 5-HT6 has 
significant positive impact on cognitive impairment. Sufferers from diseases such as 
Alzheimer’s and schizophrenia could potentially have an effective treatment (Liu et al., 
2009) within the next decade. In 2012 researchers synthesised a group of benzoisothiazole 
derivatives that contained a N,N-dimethlyformimidamide group of which two of the 
compounds displayed promising activity as potential 5-HT6  antagonists (Yoo, Hayat, Rhim, & 
Park Choo, 2012). 
 
A series of benzo[d]isothiazole-1,1-dioxides were synthesised that inhibited HCV polymerase 
NS5B. The investigation used structure based design and structure-activity relationships 
which lead to the addition of a high affinity methyl sulphonamide group (de Vicente et al., 
2009). Initially this research group focused on the use of a benzothiazine ring which showed 
potent inhibition of HCV polymerase. However these compounds had low oral bioavailability 
and high clearance in rats. The benzothiazines ring was then replaced with a 
benzo[d]isothiazole-1,1-dioxide (see figure 6) and the new compounds displayed moderate 
inhibition of the HCV polymerase NS5B (non-structural protein 5 B, this protein is 
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synthesised by the Hep C virus) (Golub et al., 2012). Previous work conducted by this 
research group showed that the addition of a methylsulphonamide group greatly increased 
potency however it was ineffective in inhibiting the replication of the virus. A methylene 
spacer group was introduced between the benzo[d]isothiazole-1,1-dioxide ring and the 
sulphonamide group, which maintained the potency against the enzyme and increased the 
replicon potency. 
 
1.10.2 Pyrazine 
Pyrazine (paradiazine) is a symmetrical nitrogen containing heterocycle component which is 
found in a wide variety of drugs, cosmetics and flavour enhancing compounds. Pyrazine 
derivatives are ubiquitous in medicine and also excellent starting points in the synthesis of 
complex heterocycles. Pyrazine derivatives have been reported to have a wide range of 
antimicrobial properties, as well as controlling allergic reactions (Myadaraboina, Alla, 
Saddanapu, Bommena, & Addlagatta, 2010). 
Pyrazinamide 9 has been used to treat tuberculosis (TB) and is still the front line drug, 
although more recently it has been used in combination with rifampicin and isoniazid. These 
three drugs have become the gold standard for TB treatment (Mitchison & Fourie, 2010). 
 
9 
Figure 7: shows the structure of pyrazinamide 9. 
The latest research into TB has been coupled with HIV sufferers; TB has become the leading 
cause of death amongst HIV/AIDS patients. Treating physicians are faced with the dilemma 
of not knowing which pathogen to treat first as TB increases drug resistance to anti-HIV 
agents and HIV allows M.tuberculosis to become a more effective opportunistic pathogen 
(Munawwar & Singh, 2012). 
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Glipizide 10 is an anti-diabetic drug belonging to the sulphonylurea group of drugs. This drug 
contains a pyrazine ring (Mallikarjun, Ravi, Babu, Kiran, & Kumar, 2009). Amiloride 11 is a 
potassium sparing diuretic, that has been used in the treatment of congestive heart failure, 
hypertension and long term use of this drug has been reported to prevent the development 
of stomach, colon and pancreatic cancer (Tatsuta et al., 1997). 
 
 
 
 
 
      
10     11 
 
Figure 8: shows the structure of glipizide 10 and amiloride 11. 
 
Pyrazine derivates play an important role in the food industry; aroma and flavours of many 
food groups are the result of pyrazine derivatives. Trying to isolate specific derivatives of 
pyazine is an ongoing investigation by the food industry; by isolating the pyrazines 
responsible for specific aromas and flavours is key to enhancing the quality of already 
existing food products on the market (Plutowska & Wardencki, 2007). 
Pyrazole is a five membered heterocycle that contains two nitrogen atoms, which is found in 
a wide variety of biologically active compounds. Figure 8 shows two pyrazole derivatives, 
compound 12 has shown anti-inflammatory, antipyretic and antinociceptive properties 
(Malvar et al., 2014) and compound 13 is a pyrazole-benzimidazole derivative that has 
displayed potent antitumour activity (Zheng et al., 2013).  
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12       13 
Figure 9: shows structures of compound 12 and 13 
 
1.10.3 Current research into heterocyclic systems as biologically active compounds. 
From the literature available there is a lot of evidence supporting the idea of combining 
heterocycles to produce novel and biologically important compounds (Kaushik et al., 2013). 
In a review by Kaushik and co-workers there is an extensive amount of research into the 
biological importance of indole and indole derivatives. From this review the wide variety of 
biological importance exerted by indole derivatives are highlighted. Odansetron 14 is a drug 
given to patients who have undergone chemotherapy to deal with sickness and 2-aryl-3-
arylcorbonylindole 15 an anticancer agent which have shown to inhibit tubulin 
polymerization and oxpertine 16, which is an antipsychotic (see figure 9). 
 
 14     15     16 
Figure 10: structure for odansetron 14, an anticancer 2-aryl-3-arylcorbonylindole 15 and 
oxpertine 16. 
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A review article by Ali and Siddiqui discussed the pharmacological importance of the 
benzothiazole nucleus. The review article stated that this particular heterocyclic system 
displayed a range of diverse biological importance such as anti-cancer, antiviral and 
anticonvulsant properties. In addition the review article also stated that the benzothiazole 
ring system was a good template for the development of novel biological compounds (Ali & 
Siddiqui, 2013) 
A review article by Rudrapal and De focuses on the biological importance of heterocyclic 
Schiff bases. Schiff’s bases are known for their broad spectrum of biological activity due to 
the presence of an imine bond. This review includes a vast number of heterocyclic systems 
including sulphur nitrogen heterocycles, as biologically important compounds (Rudrapal & 
De, 2013) 
Recent research on heterocyclic systems that include sulphur, nitrogen and oxygen has 
revealed that novel derivatives of bis-benzothiazolyl-pyridines and pyrazine have displayed 
strong antiproliferative activity. It has been strongly suggested that the synthesized 
heterocycles work by exerting oxidative stress on the cancer cells (Myadaraboina et al., 
2010). 
In the last three years there has been a lot of interest in aurora kinase inhibitor molecules 
being synthesised as possible anti-cancer agents. In 2010 a series of novel imidazo[1,2-
a]pyrazine aurora kinase inhibitors were synthesized and investigated (Belanger et al., 
2010). The aurora kinase family regulate mitosis, over expression of all three mammalian 
aurora kinases (aurora A, B & C) have been found in human cancer cells; however the 
implication of these kinases (aurora C) in tumour development has not been ascertained 
(Katayama & Sen, 2010). 
A recent review article on kinase activators as novel antidiabetic agents, focused on 
designing a set of compounds that would activate glucokinase, which is the enzyme 
responsible to glucose homeostasis in the body (Matschinsky, 2009). Through structure 
activity relationships (SAR) the starting compound was a 2-methybenzofuran 17 scaffold 
from which various structurally diverse analogs were prepared. The review also included the 
study and discovery of imidazo derivative 18  and related structures see figure 10 (Castro, 
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2012). Both compounds 17 and 18 are currently undergoing clinical evaluation for type 2 
diabetes mellitus patients. 
 
 
 
 
 
 
17         18 
 
Figure 11: shows a 2-methylbenzofuran derivative 17 and imidazo derivative 18. that is 
currently in phase 1 of clinical trials (Castro, 2012). 
Chikalia and co-workers synthesized a library of twenty benzimidazole-1,3,4-oxadiazole 
derivatives and screened all twenty compounds against a variety of bacteria, fungi and have 
screened them for potential antituberculosis activity. These compounds displayed 
antibacterial activity at concentrations as low as 4 µgmL and similar results for 
antituberculosis activity (Patel, Patel, Kumari, Rajani, & Chikhalia, 2012).  
Heterocyclic systems are found in many anti-inflammatory agents such as indomethacin 19, 
celecoxib 20 and piroxicam 21 (see figure 11). More common anti-inflammatory agents such 
as ibuprofen are known as  non steroidal anti-inflammatory drugs (NSAIDs) which are the  
most widely used anti-inflammatory agents, with aspirin being marketed in 1860 (Rao, 
Knaus, Road, & Jolla, 2008) and has remained a gold standard since then. From the 
development of acetylsalicylic acid (aspirin) there have been a number of breakthroughs in 
the understanding of inflammatory processes. The elucidation of cylcooxygenase enzymes 
has helped combat gastrointestinal related side effects caused by older generation NSAIDs. 
Drugs such as Ibuprofen and diclofenac are the most frequently prescribed antinociceptive 
and anti-inflammatory agents. Over the last 50 years steroids have been used to treat 
28 
 
chronic inflammatory diseases (DeNatale, Rosenberg, & Gharibo, 2010), however over use 
of drugs such as corticosteroids have revealed the detrimental effects long term use of 
steroids. Many drugs will exhibit complication such as resistance or damaging side effects 
when overused, therefore it is necessary to either limit the amount of drugs we take or 
continually strive to improve upon the drugs already in use. Constant research is being 
conducted into the improvement of failing drugs in a broad range of drug classes.   
   
 
Figure 12: structures of indomethacin 19, celecoxib 20 and piroxicam 21. 
To our knowledge, the literature shows no information on benzoisothiazoles fused to 
pyrazine rings as biologically active molecules. There are a small number of articles that 
report benzoisothiazoles derivatives as being possible drug like molecules with a broad 
spectrum of biological importance (Yadav & Senthilkumar, 2011).  
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The research proposed aims to explore the biological properties of benzoisothiazoles fused 
to pyrazine rings. The aim of the current research was to synthesize 
benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide derivatives. For this, chalcone dibromo 
sulphonyl chloride were used as a starting materials and ethanol as a solvent, these 
precursors were synthesized in the laboratory during a previous project (see scheme 1). The 
resultant product was characterised by using different analytical techniques. The novel 
library which was successfully synthesized and characterized was then screened for 
antimicrobial activity. 
  
Scheme 1: Shows the general procedure for synthesis of the precursor used for the 
synthesis of benzoisothiazole derivatives. 
The final sulphonyl chloride precursors were previously synthesized in the lab, from these 
precursors a series of benzoisothiazole derivates will be synthesised and then screened for 
any biological activity. 
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1.10.4 Biological screening 
We aimed to screen all the compounds synthesized for a range of different biological 
activities these include antimicrobial, antifungal, anti-inflammatory, tuberculosis and 
possibly screen some of the compounds for any activity regarding the CNS. For the 
antimicrobial screening the compounds will be tested using disk diffusion methods and well 
diffusion approach which are described in a review by Ncube et al (Ncube, Afolayan, & 
Okoh, 2008). 
For bacterial cell viability testing MTT assay will be employed. MTT assay was first described 
in 1983 by Tim Mosmann, this is a colorimetric technique used in mammalian cells. A yellow 
tetrazolium salt is reduced to a purple formazan; this method is to provide quantitative data 
on living or surviving cells. The yellow solution is reduced by mitochondrial dehydrogenase 
enzymes present in active/living cells; it is common practise to assume that the colour 
intensity of the purple formazan is directly proportional to the amount of viable cells 
present. However the mechanism in which the MTT works has been questioned due to the 
fact that bacteria do not possess mitochondria. It is has been surmised that MTT is mainly 
reduced by NADH in the cytoplasm and some dehydrogenases associated with the 
endoplasmic reticulum (Stockert, Blázquez-Castro, Cañete, Horobin, & Villanueva, 2012). 
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Chapter 2 
2.1 General methods for synthesis of benzoisothiazole derivatives 
All the chemicals were purchased from Sigma Aldrich and used in the reactions without any 
prior purification. Melting point ranges were determined using a Gallenkamp melting point 
apparatus. The NMR spectra were recorded using a JeolDextra NMR spectrometer at 
600MHz spectrometer with tetramethylsilane as internal standard and solvents as indicated. 
Chemical shifts were measured in ppm (δ) relative to TMS (0.00 ppm). Coupling constants (Ј) 
are reported in Hertz (Hz). The following abbreviations are used to describe the signal 
multiplicities: s (singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Infrared 
spectra were recorded with a Varian spectrophotometer as KBr discs (0.080 g of KBr + 
0.0015 g of compound). TLC (thin layer chromatography) was performed using silica gel 
plates by dissolving the compound in ethyl acetate and using the solvent system 
cyclohexane:ethyl acetate; 2:1. 
 
2.2 Liquid chromatography Mass Spectroscopy (LC-MS) 
Samples were obtained with a VG Micromass V15 spectrometer operating at 70 eV (Varian: 
210 LC pumps × 2, 1200L Quadrapole MS/MS, 410 autosampler) using a gradient solvent 
system of A: Water/0.1% formic acid and B: acetonitrile/ 0.1% formic acid. Electrospray 
ionisation was employed. 
 
2.3 X-ray Crystallography  
X-Ray analysis has also been used to determine the structure of one of the compounds. The 
sample of a crystalline compound was diffracted by X-rays. From the diffraction pattern it is 
possible to predict the spatial arrangement of the atoms in a molecule and therefore 
characterise the compound. X-Ray analysis was carried out at the University of Nottingham 
by Dr Lee Martin. 
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2.4 General method for synthesis of benzo[4,5]-isothiazolo[2,3-a]-pyrazin-1-yl) (phenyl) 
methanones (22-39)  
To a stirred solution of the chalcone dibromo sulphonyl chloride (1g) in ethanol (25 ml) was 
added 1,2-diaminopropane (2 mole equivalent). The reaction mixture was warmed on a 
water bath for 10-15 minutes until all the solid had dissolved. The reaction mixture was 
allowed to cool to room temperature and the resulting solid was filtered and air dried. The 
product was purified by recrystallization from the appropriate solvent. 
 
 
 
 
 
 
 
Scheme 2: Shows the general procedure for synthesis of the final step in the synthesis of 
benzoisothiazole fused pyrazine derivatives. 
 
 
 
 
 
 
 
 
EtOH/RT 
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Compound R1 R2 R3 R4 % Yield m.p. (°C) m/z (M+H) 
22 H H H H 29 219-220 402.3 
23 H H CH3 H 47 180-181 416.3 
24 H H F H 30 181-182 420.2 
25 H H Cl H 43 204-205 436.2 
26 H H Br H 48 204-205 480.4 
27 H Cl H H 79 194-195 436.2 
28 H Br H H 50 189-190 482.7 
29 Cl H H H 46 215-216 436.5 
30 Br H H H 75 195-196 480.4 
31 H H H CH3 34 163-164 416.3 
32 H H CH3 CH3 64 205-206 430.3 
33 H H F CH3 12 175-176 434.3 
34 H H Cl CH3 39 180-181 450.2 
35 H H Br CH3 45 195-196 494.1 
36 H Cl H CH3 54 179-180 450.2 
37 H Br H CH3 80 175-176 495.9 
38 Cl H H CH3 64 191-192 452.2 
39 Br H H CH3 29 201-202 498.6 
 
Table 3:  shows data for compounds 22-39.  
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2.5 Results for Compounds (22-39) 
 
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(Phenyl)methanone (22) 
Re-crystallizing solvent used: Ethanol. Yellow crystals were obtained (29% yield); Melting 
Point: 219-220oC; IR (KBr cm-1): 3337 (NH), 1681 (C=O), 1287 , 1176 (SO2); 
1H NMR (CDCl3): δ 
1.8 (d, 3H, CH3 J = 6.42 Hz), δ 1.75 (s, 1H, NH), δ 2.88 (s, 1H, CH), δ 3.45 and δ 3.73 (d, 2H, 
CH2 J = 12.00 Hz), δ 3.51 (s, 3H, OCH3), δ 3.91 (s, 3H, OCH3), δ 4.45 (d, 1H, CH J = 10.09 Hz) δ 
4.68 (d, 1H, CH J = 10.09 Hz), δ 6.43 (s, 1H, CH), δ 7.24 (s, 1H, Ar-H), δ 7.45 (d, 2H, Ar-H J = 
7.32 Hz), δ 7.60 (s, 1H, Ar-H), δ 7.93 (d, 2H, Ar-H J = 8.25); 13C NMR (CDCl3) δ 18.80, 47.20, 
48.20, 55.93, 56.31, 58.40, 62.40, 102.72, 107.25, 126.33, 128.98,  129.02, 134.42, 135.42, 
150.38, 152.53, 198.21 (C=O); MS (m/z): (M+H)+ 402.3. 
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(p-tolyl)methanone (23) 
Re-crystallizing solvent used: Ethanol. White crystals were obtained (47% yield); Melting 
Point: 180-181oC; IR (KBr cm-1): 3447 (NH), 1663 (C=O), 1284, 1140 (SO2): 
1H NMR (CDCl3): δ 
1.14 (d, 3H, CH3), δ 1.54 (s, 3H, CH3), δ 1.73 (s, 1H, NH), δ 2.37 ( s, 1H, CH), δ 2.39 and δ 2.43 
(s, 2H, CH2), δ 3.44 (s, 3H, OCH3), δ 3.88 (s, 3H, OCH3), δ 4.45 (d, 1H, CH), δ 4.65 (d, 1H, CH), 
δ 6.35- 7.78 (m, 6H, Ar-H) ; 13C NMR (CDCl3) δ 21.74, 22.10, 55.87,  56.33, 60.40, 102.71, 
107.10, 126.10, 129.22, 129.69, 132.10, 151.30, 152.10, 198.21 (C=O); MS (m/z): (M+H)+ 
416.3.  
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(4-fluorophenyl)methanone (24) 
Re-crystallizing solvent used: Ethanol. Yellow crystals were obtained (30% yield); Melting 
Point: 181-182oC; IR (KBr cm-1): 3297 (NH), 1677 (C=O), 1290, 1144 (SO2); 
1H NMR (CDCl3): δ 
1.75 (s, 3H, CH3), 3.51 (s, 3H, OCH3), 3.93 (s, 4H, OCH3, CH), 4.43-4.46 (s, 2H, CH2), 6.43-7.94 
(m, 6H, Ar-H) ; 13C NMR (CDCl3) δ 18.80, 47.20, 48.20, 55.93, 56.31, 58.40, 62.40, 102.72, 
107.25, 126.33, 128.98, 129.02, 134.42, 135.42, 150.38, 152.53, 198.21 (C=O); MS (m/z): 
(M+H)+ 420.2.  
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(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl) (4-chlorophenyl)methanone (25) 
Re-crystallizing solvent used: Ethanol. Yellow crystals were obtained (43% yield); Melting 
Point: 204-205oC; IR (KBr cm-1): 3468 (NH), 1672 (C=O), 1284, 1142 (SO2); 
1H NMR (CDCl3): δ 
1.75 (s, 3H, CH3), 3.51 (s, 3H, 0CH3), 3.93 (s, 4H, OCH3, CH), 4.43-4.46 (s, 2H, CH2), 6.43-7.94 
(m, 6H, Ar-H) ; 13C NMR (CDCl3) δ 18.80, 47.20, 48.20, 55.93, 56.31, 58.40, 62.40, 102.72, 
107.25, 126.33, 128.98, 129.02, 134.42, 135.42, 150.38, 152.53, 198.21 (C=O); MS (m/z): 
(M+H)+ 436.2  
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(4-bromophenyl)methanone (26) 
Re-crystallizing solvent used: Ethanol. Yellow crystals were obtained (48% yield); Melting 
Point: 204-205oC; IR (KBr cm-1): 3458 (NH), 1672 (C=O), 1284, 1141 (SO2); 
1H NMR (CDCl3): δ 
1.75 (s, 3H, CH3), 3.51 (s, 3H, OCH3), 3.93 (s, 3H, OCH3), 4.43-4.46 (ss, 2H, CH2), 6.43-7.94 (m, 
6H, Ar-H) ; 13C NMR (CDCl3) δ 18.80, 47.20, 48.20, 55.93, 56.31, 58.40, 62.40, 102.72, 107.25, 
126.33, 128.98, 129.02, 134.42, 135.42, 150.38, 152.53, 198.21 (C=O); MS (m/z): (M+H)+ 
480.4  
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(3-chlorophenyl)methanone (27)  
Re-crystallizing solvent used: Ethanol. Light yellow crystals were obtained (79% yield); 
Melting Point: 194-195oC; IR (KBr cm-1): 1691 (C=O), 1270, 1158 (SO2); 
13C NMR (CDCl3) δ 
14.78, 41.77, 43.33, 46.23, 56.45, 56.57, 67.33, 105.67, 110.89, 111.89, 111.93, 127.07, 
128.91, 130.37, 131.23, 134.19, 135.12, 149.21, 154.67, 188.60 (C=O); M.S (m/z): 436.2 
(M+H)+ 
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(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(3-bromophenyl)methanone (28) 
Re-crystallizing solvent used: Ethanol. Yellow crystals were obtained (50% yield); Melting 
Point: 189-190oC; IR (KBr cm-1): 3455 (NH), 1686 (C=O), 1290, 1140 (SO2); 
1H NMR (CDCl3): δ 
1.45 (d, 3H, CH3 J = 7.34 Hz), 3.60-3.61 (d, CH2, 2H J = 14.7 Hz),  (s, 3H, OCH3), 3.93 (s, 3H, 
OCH3), 4.33-4.36 (d, H, CH J = 10.09 Hz), 4.65-4.66 (d, H, CH J = 9.17 Hz), 6.46-8.08 (m, 6H, 
Ar-H) ; 13C NMR (CDCl3) δ 18.80, 47.27, 48.26, 56.05, 56.34, 58.00, 62.74, 102.80, 106.65, 
107.13, 123.35, 126.34, 127.63, 127.71, 130.47, 131.78, 137.12, 150.48, 152.66, 197.04 
(C=O); M.S (m/z): (M+H)+  482.7.  
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(2-chlorophenyl)methanone (29) 
Re-crystallizing solvent used: Ethanol. Yellow crystals were obtained (46% yield); Melting 
Point: 215-216oC; IR (KBr cm-1): 3388 (NH), 1683 (C=O), 1290, 1190 (SO2); MS (m/z): (M
+H)+  
436.5.  
(8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5]isothiazolo[2,3-
a]pyrazin-1-yl)(2-bromophenyl)methanone (30) 
Re-crystallizing solvent used: Ethanol. Orange crystals were obtained (75% yield); Melting 
Point: 195-196oC; IR (KBr cm-1): 3084 (NH), 1682 (C=O), 1286, 1123 (SO2); 
1H NMR (CDCl3): δ 
1.21 (s, 3H, CH3), 1.15 (d, 2H,CH2), 3.57 (s, 3H, OCH3), 3.67-3.66 (d, 1H, CH J =10.54 Hz), 3.68 
(s, 3H, OCH3), 4.18-4.59 (dd, 2H, CH2 J = 9.17 Hz, J = 10.09 Hz), 6.43-8.06 (m, 6H, Ar-H); 
13C 
NMR (CDCl3) δ 18.40, 18.72, 47.16, 48.31, 48.31, 57.97, 58.42, 62.69, 102.81, 107.15, 
123.35, 126.35, 127.65, 130.48, 131.75, 137.14, 150.51, 152.66, 196.92 (C=O);  MS (m/z): 
(M+H)+  480.4. 
 
 
 
 
37 
 
To a stirred solution of chalcone dibromo sulphonyl chloride (1g) in ethanol (25 ml) was 
added 2-methyl-1,2-diaminopropane (2 mole equivalent). The reaction mixture was warmed 
on a water bath for 10-15 minutes until all the solid had dissolved. The reaction mixture was 
allowed to cool to room temperature and the resulting solid was filtered and air dried. The 
product was purified by recrystallization from the appropriate solvent. 
 
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(Phenyl)methanone (31) 
Re-crystallizing solvent used: Ethanol. White needle shaped crystals were obtained (34% 
yield); Melting Point: 163-164oC; IR (KBr cm-1): 3420 (NH), 1676 (C=O), 1277, 1141 (SO2); 
1H 
NMR (CDCl3): δ 1.24 (s, 3H, CH3), 1.41 (s, 3H,CH3), 3.46 (s, 3H, OCH3), 3.64–3.66 (d, 1H, CH J = 
12.84 Hz), 3.89 (s, 3H, OCH3), 4.51-4.59 (dd, 2H, CH2 J = 9,17 Hz), 6.37-7.98 (m, 7H, Ar-H); 
13C 
NMR (CDCl3) δ 23.10, 28.25, 49.86, 55.83, 56.34, 57.93, 58.69, 102.73, 106.71, 126.76 
129.09, 134.49, 135.59, 150.46, 152.62, 186.45 (C=O); MS (m/z): (M+H)+  416.3  
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(p-tolyl)methanone (32) 
Re-crystallizing solvent used: Ethanol. Light yellow crystals were obtained (64% yield); 
Melting Point: 205-206oC; IR (KBr cm-1): 3312 (NH), 1660 (C=O), 1275, 1177 (SO2); 
1H NMR 
(CDCl3): δ 1.21 (s, 3H, CH3), 1.38 (s, 3H,CH3), 2.39 (s, 3H, CH3), δ 1.65 (s,1H, NH), δ 3.44 (s, 
3H, OCH3), δ 2.93 and δ 3.63 (d, 2H, CH2 J = 12.84 Hz), 3.88 (s, 3H, OCH3), 4.45 (s,1H, CH), 
4.53 (s, 1H, CH), 6.36-7.86 (m, 6H, Ar-H); 13C NMR (CDCl3) δ 21.73, 23.17, 28.32, 49.90, 
55.76, 56.30, 57.84, 58.79, 102.65, 106.74, 126.71, 126.71, 129.18, 129.72, 133.14, 145.65, 
150.36, 152.54, 198.06 (C=O); MS (m/z): (M+H)+  430.3  
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(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(4-fluorophenyl)methanone (33) 
Re-crystallizing solvent used: Ethanol. White crystals were obtained (12% yield); Melting 
Point: 175-176oC; IR (KBr cm-1): 3438 (NH), 1677 (C=O), 1289, 1180 (SO2); 
1H NMR (CDCl3): δ 
1.23 (s, 3H, CH3), 1.41 (s, 3H,CH3), 3.54 (s,3H, OCH3), 3.65 (d, 1H, CH J = 13.74 Hz), 3.89 (s, 
3H, OCH3), 4.43 (s, 1H, CH), 6.41-8.03 (m, 6H, Ar-H); 
13C NMR (CDCl3) δ 22.98, 55.89, 56.36, 
58.35, 76.79, 77.00, 77.21, 102.78, 106.65, 116.25, 116.39, 126.81, 131.92, 152.70, 195.67; 
MS (m/z): (M+H)+  434.3  
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(4-Chlorophenyl)methanone (34) 
Re-crystallizing solvent used: Ethanol. Light yellow crystals were obtained (39% yield); 
Melting Point: 180-181oC; IR (KBr cm-1): 3442 (NH), 1665 (C=O), 1290, 1182 (SO2); 
1H NMR 
(CDCl3): δ 1.24 (s, 3H, CH3), 1.41 (s, 3H, CH3), 2.95 (d, 1H, CH J = 12.84 Hz), 3.57 (s, 3H, OCH3), 
3.67 (d, 1H, CH J = 13.74 Hz), 3.91 (s, 3H, OCH3), 4.43 (s, 1H, CH), 4.61 (s, 1H, CH), 6.43-7.95 
(m, 6H, Ar-H); 13C NMR (CDCl3) δ23.03, 28.25, 49.87, 55.90, 56.33, 58.21, 58.31, 102.75, 
106.62, 126.79, 126.96, 129.37, 130.46, 133.79, 141.07, 150.52, 152.68, 197.31 (C=O); MS 
(m/z): (M+H)+  450.2 
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(4-bromophenyl)methanone (35) 
Re-crystallizing solvent used: Ethanol. Light yellow crystals were obtained (45% yield); 
Melting Point: 195-196oC; IR (KBr cm-1): 3447 (NH), 1663 (C=O), 1290, 1182 (SO2); 
1H NMR 
(CDCl3): δ 1.24 (s, 3H, CH3), 1.41 (s, 3H, CH3), 2.96 (d, 1H, CH J = 13.75 Hz), 3.57 (s, 3H, OCH3), 
3.91 (s, 3H, OCH3), 3.67 (d, 1H, CH J = 13.74 Hz), 4.42 (s, 1H, CH), 4.61 (s, 1H, CH), 6.42-7.86 
(m, 6H, Ar-H); 13C NMR (CDCl3) δ 23.03, 28.25, 49.43, 49.86, 55.91, 56.34, 58.20, 58.30, 
102.76, 106.62, 126.79, 126.94, 129.88, 130.50, 132.38, 134.16, 150.52, 152.68, 197.53 
(C=O) MS (m/z): (M+H)+  494.1 
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(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(3-chlorophenyl)methanone (36) 
Re-crystallizing solvent used: Ethanol. Light yellow crystals were obtained (54% yield); 
Melting Point: 179-180oC; IR (KBr cm-1): 3449 (NH), 1681 (C=O), 1275, 1190 (SO2); 
1H NMR 
(CDCl3): δ 1.23 (s, 3H, CH3), 1.41 (s, 3H,CH3), 1.55 (s, 1H, CH), 3.57 (s, 3H, OCH3), 3.65 (s, 1H, 
CH), 3.89 (s, 3H, CH3), 4.41 (s, 1H, CH), 4.61 (s,1H,CH), 6.41 (s, 1H, CH), 7.22-7.24 (d, 1H, Ar-H 
J = 5.87 Hz), 7.39-7.42 (t, 1H, Ar-H J = 7.79 Hz), 7.56 (d, 1H, Ar-H J = 7.34 Hz), 7.82-7.97 (d, 
2H, Ar-H J = 8.25 Hz), 7.98 (s, 1H, CO); 13C NMR (CDCl3) δ 22.97, 28.18, 49.83, 55.97, 56.36, 
58.25, 58.40, 76.79, 77.00, 77.21, 102.80, 106.61, 126.81, 127.22, 128.98, 130.35, 134.28, 
137.05, 150.58, 152.76, 198.50 (C=O); MS (m/z): (M+H)+  494.1 
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(3-bromophenyl)methanone (37) 
Re-crystallizing solvent used: Ethanol. Light yellow crystals were obtained (80% yield); 
Melting Point: 175-176oC; IR (KBr cm-1): 3447 (NH), 1681 (C=O), 1265, 1190 (SO2); 
1H NMR 
(CDCl3): δ 1.24 (s, 3H, CH3), 1.41 (s, 3H, CH3), 2.96 (s, 1H, CH3), 2.92-2.94 (d, 1H, NH), 3.60 (s, 
3H, OCH3), 3.67 (d, 1H, CH), 3.91 (s, 3H, OCH3), 4.42 (d, 1H, CH J = 12.00 Hz), 4.62 (d, 1H, CH),  
6.44 (s, 1H CH), 7.34- 7.73 (t, 2H, CH J = 7.84 Hz), 7.74-7.75 (d,2H, Ar-H J = 9.17 Hz), 7.88-
7.89 (d, 2H, Ar-H J = 7.43), 8.16 (s, 1H, Ar-H); 13C NMR (CDCl3) δ 22.98, 28.23, 49.86, 55.98, 
56.35, 58.25, 58.43, 102.79, 106.62, 123.40, 126.80, 127.64, 130.55, 131.94, 137.15, 137.25, 
150.57, 152.76 198.80 (C=O); MS (m/z): (M+H)+  495.9 
(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(2-Chlorophenyl)methanone (38) 
Re-crystallizing solvent used: Ethanol. White crystals were obtained (34% yield); Melting 
Point: 195-195.5oC; IR (KBr cm-1): 3448 (NH), 1720 (C=O), 1297, 1179 (SO2); 
1H NMR (CDCl3): 
δ 1.44 (s, 3H, CH3), 1.58 (s, 3H, CH3),  3.22 (d, 1H, CH J = 13.75), 3.66 (d, 1H, CH J = 14.64 Hz), 
3.68 (d, 1H, CH), 3.93 (s, 6H,), 4.62 (d, 1H, CH J = 11.00 Hz), 6.76-7.41 (m, 6H, Ar-H); 13C NMR 
(CDCl3) δ 23.17, 31.25, 42.10, 50.67, 56.46, 58.11, 59.96, 102.81, 104.69, 121.90, 127.46, 
129.61, 129.78, 129.92, 143.35, 145.55, 150.68, 153.66, 164.88, 199.80 (C=O); M.S (m/z): 
(M+H)+  452.2 
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(8,9-Dimethoxy-3,3-dimethyl-6,6-dioxido-2,3,4,10b-tetrahydro-1H-benzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(2-bromophenyl)methanone (39) 
Re-crystallizing solvent used: Ethanol. White crystals were obtained (29% yield); Melting 
Point: 201oC-202oC; IR (KBr cm-1): 3467 (NH), 1715 (C=O), 1297, 1179 (SO2); 
1H NMR (CDCl3): 
δ 1.44 (s, 3H, CH3), 1.58 (s, 3H, CH3),  3.22 (d, 1H, CH J = 13.75 Hz), 3.66 (d, 1H, CH J = 7.34 
Hz), 3.68 (d, 1H, CH J = 7.34 Hz), 3.93 (s, 6H), 4.62 (d, 1H, CH J = 12.0 Hz), 6.76-7.41 (m, 6H, 
Ar-H); 13C NMR (CDCl3) δ 23.17, 31.25, 42.10, 50.67, 56.46, 58.11, 59.96, 102.81, 104.69, 
121.90, 127.46, 129.61, 129.78, 129.92, 143.35, 145.55, 150.68, 153.66, 164.88, 199.80 
(C=O); MS (m/z): (M+H)+  498.6 
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Chapter 3 
3.1 Biological screening methodology  
All eighteen compounds were screened against 4 types of bacteria, 3 types of fungi. Before 
biological testing could be conducted an appropriate solvent needed to be selected. 
 
3.2 Bacterial Culture and identification 
Culture strains of Bacillus subtilis ATCC 6633, Staphylococcus aureus ATCC 6538, Escherichia 
coli ATCC 11775 and Proteus hauseri ATCC 13315 were obtained from the Culture collection 
of University of Hertfordshire. Streaked agar plates were provided, to conduct gram staining 
and antibacterial screening, inoculums had to be prepared. 
 Bacillus subtilis - gram-positive bacteria found in soil, has excellent fermentation 
capacities.(Zweers et al., 2008) This bacteria was selected as its related to Bacillus 
cereus which can cause food borne illnesses. 
 Escherichia coli - rod shaped gram negative, found in lower intestines of warm 
blooded animals, and recent investigations has shown that the presence of E. coli 
has been strongly linked to both Crohn’s disease and inflammatory bowel disease 
(Barnich, Denizot, & Darfeuille-Michaud, 2013) 
 Proteus hauseri – rod shaped gram negative bacterium that has been linked with 
nosocomial disease and urinary tract infections (O’Hara Et al 2000). 
 
 Staphylococcus aureus – coccal shaped gram positive bacterium. Although S. aureus 
has been extensively reported as a lethal human pathogen it is often ignored that 
many strains of this bacteria are commensal (Kim, Missiakas & Schneewind, 2014) 
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Bacteria ATCC number University 
record number 
Bacillus subtilis 6633 B30 
Escherichia coli 11775 B285 
Staphylococcus aureus 6538 B9 
Proteus hauseri 13315 B15 
Table4: Bacterial cultures and their record numbers 
 
3.3 Inoculum preparation. 
Colonies were derived from streaked agar plates were used for gram staining. To prepare 
inoculums for antibacterial screening the flame loop technique was used and universal 
bottles containing autoclaved Mueller Hinton (MH) broth were inoculated and the 
incubated. After 6-8 hours the inoculum was ready to be used in biological testing before 
placing the inoculum into microtitre plates it was necessary to know the concentration of 
cells, using McFarland’s solution the bacterial culture could be adjusted to a fixed density 
(see McFarland’s solution preparation).  
All bacteria were cultured using Mueller Hinton broth and incubated ay 37oC. 
Mueller Hinton broth was prepared by adding 21 g of MH broth powder to 1 litre of distilled 
water; the broth was then autoclaved and kept in an aseptic environment.  
 
3.4 Gram staining technique. 
The bacterial cultures provided were further validated by using the gram staining technique. 
The method used is described by Reed et al using a clean microscope slide, a small volume 
(10-30 µl) of bacterial inoculum was placed on the slide and left to dry.  The bacterial smear 
is then heat fixed by passing it through the blue flame of a Bunsen burner. The slide is the 
flooded with crystal violet dye mixture. The slide is then rinsed under tap water and stained 
with Gram’s iodine again rinsed with tap water. The counter stain carbonyl fushin is then 
applied for 10-15 seconds and rinsed with tap water. Once all the water has been removed a 
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drop of immersion oil is placed on the smear and the slide is then ready to be examination 
under microscope (Reed, Holmes, Weyers & Jones, 2007). 
3.5 Solubility 
The library of compounds was tested for solubility in a range of solvents; these solvents 
include ethanol, methanol, ethyl acetate, dichloromethane, DMSO, acetone and 
acetonitrile. Of all solvents tested the compounds were only soluble in DMSO and hot 
ethanol. The compounds were soluble in acetone, however as this solvent is so volatile it 
was inappropriate to use for biological screening. As the compounds were readily soluble in 
DMSO this was chosen as the appropriate solvent. 
Dimethyl sulphoxide at certain concentrations has been reported as being cytotoxic to a 
variety of bacteria, fungi and mammalian cells (Da Violante et al., 2002). As DMSO was the 
solvent of choice, it was necessary to ascertain what the maximum concentration or 
percentage of DMSO that could be implemented in the biological tests.  
 
3.6 Maximum DMSO concentration testing. 
Using a microtitre plate 8 different concentrations of DMSO were tested the highest 
concentration was 10% and the lowest was 3% against all four bacteria. Dilutions were 
made using eppendorf tubes. A series of dilutions were made using pure 100% DMSO and 
sterile distilled water see table for dilutions. Each well could hold a maximum volume of 200  
µl. From this experiment it was concluded that a maximum of 5% DMSO could be tolerated 
by the cells. (See results section for graphs) 
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Amount of 
inoculum in µl 
(bacteria + MH 
broth) 
Amount of DMSO 
(100%) in µl 
Percentage DMSO 
(%) 
194 6 3 
192 8 4 
190 10 5 
188 12 6 
186 14 7 
184 16 8 
182 18 9 
180 20 10 
 
Table 5: shows the volumes of Muller Hinton (MH) broth and DMSO (100%) to make up the 
different percentages of DMSO. 
 
3.7 Stock Solution of benzoisothiazole derivatives 
20 mg of each benzoisothiazole compound was weighed and dissolved in 1 ml of DMSO 
(99.98%; Fischer Chemical). The Stock solutions were preserved at - 20°C. The compounds 
were tested for solubility in a wide range of solvents however the compounds were only 
readily soluble in DMSO and boiling ethanol. 
 
3.8 Streptomycin (control) Stock: 
Streptomycin sulphate salt powder (5g; Sigma Aldrich) was weighed and dissolved in 1ml of 
sterile distilled water. This was used as a control for antimicrobial testing to compare the 
activity of synthesized benzoisothiazoles. The concentration of 1 mg ml-1 was used for all 
antibacterial testing.  
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3.9 MTT dye: (0.2 mg/ml). 
MTT (2 mg; 3-4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide, a tetrazole) dye 
(≥97.5%, Sigma Aldrich) was weighed in a fume hood and to this 10ml of sterile distilled 
water was added under sterile conditions. The solution is stable at 0°C for six months and 
only stable for four days at 4°C. 
 
3.10 Preparation of 0.5 McFarland Standard 
0.5 McFarland standard was used as a reference to adjust the turbidity of bacterial 
suspensions, so that the number of bacteria will be within a given range of 1 to 1.5×108 
CFU/ml, for its further use for susceptibility testing or other procedures that require a 
standardization of inoculum. A 0.5 McFarland standard was prepared by mixing 0.05ml of 
1.175% barium chloride dihydrate (BaCl2.2H2O) (Sigma Aldrich), with 9.95 ml of 1% sulphuric 
acid (H2SO4) (98%, AR). After preparation, the standards were preserved at 4°C in dark 
(securely wrapping foil around the falcon). The standard can be measured by the 
absorbance of the bacterial suspension and the McFarland standard with the help of a 
spectrophotometer at 590 nm wavelength. 
All 18 compounds were soluble in DMSO; however when an aqueous medium was 
introduced into the solution a precipitate formed.  The Muller-Hinton broth used to culture 
the bacteria was made using distilled water, so it was necessary include DMSO in the broth 
to increase the solubility of the compounds. So before testing could begin the maximum 
percentage of DMSO needed to be ascertained. This percentage needed to be high enough 
to increase solubility if the compounds but cause no harm to the bacteria being tested. This 
was achieved by using a 96 microtitre plate. The four microorganisms were exposed to 
different concentrations of DMSO (3-10%). MTT solution was added to test which of the 
wells contained viable cells, the MTT solution is a colorimetric technique used to show 
viability of cells through activity in the mitochondria. Data was obtained using a plate 
reader. From the data obtained the highest that could be applied was 5% of DMSO. 
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3.10.1 Method for antibacterial screening. 
Each well in a 96 microtitre plate can accommodate 200 µl. 
 
                             Wells   1       2      3    4      5       6       7       8       9     10 
Figure 13: represents the microtitre wells. 
To well 1, 98 µl of Mueller Hinton (MH) broth was added and then a further 2 µl of pure 
DMSO was added, this gave well 1 a total of 2% DMSO. To wells 3-8 50 µl of 4% DMSO MH 
broth was added. To well 1 50 µl of bacterial culture and 50µl of compound was added 
making the total volume 200 µl. 100 µl was taken from well 1 and diluted down wells 2-8, 
this gave the wells an approximate DMSO percentage of 4.5%. Well 9 and 10 were the 
positive control (contained only culture) and negative control (contained only M-H broth).  A 
multichannel pipette was used and all tests were completed in triplicate. 
During the incubation period a small amount of condensation is formed so to minimise this, 
the outer circle of wells were filled with sterile distilled water (SDW). Due to insolubility 
issues the plates were incubated on an agitator overnight. 
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Figure 14: a 96 well microtitre plate the shaded blue circles represent the SDW. 
 
To a microtitre plate (see figure 14) 20 mg of each compound was dissolved in 1ml of DMSO 
which gave 20 mg ml-1  stock concentration. When diluted with Muller-Hinton (50 µl) broth 
and culture (50 µl) reduced this to a starting concentration of 6.67 mg ml-1 and after 8 
dilutions a final concentration of 104 µg ml-1. These values were calculated using the 
following equation. 
C1V1 = C2V2 
C1 = Starting concentration 
V1 = Starting volume 
C2 = Final concentration 
V2 = Final volume 
20 mgml x 0.05ml =? X 0.15 ml 
↓ 
20 x 0.05 = 6.67 mg ml-1 
                      0.15 
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Once the culture had been added to the plate, the absorbance was recorded at 590 nm and 
left to incubate overnight. After the incubation (16-18hrs) period the plates were re-read. 
To ascertain the activity of the compound MTT assay was used. See MTT preparation. 
To gain accurate results for the possible antimicrobial activity of each compound, the 
compounds must be subjected to the same amount of bacteria culture (ensure that all 
culture contain approximately the same amount of colony forming units CFU’s). To ensure 
that the cultures were of equal CFU’s, McFarland’s standard was used; this is a solution of 
Barium Chloride and sulphuric acid which when mixed forms a barium sulphate precipitate 
which is of a fixed density that can be used to compare the turbidity of the bacterial culture 
to provide a numerical value which can be used to determine the amount of bacteria 
present (see Mcfarland’s solution preparation)   
After the incubation period 20 µl of MTT solution was added and left to incubate for a 
further hour at 37oC. After one hour incubation the difference between viable and non-
viable cells can easily be seen. Upon the addition of MTT and wells that contain non-viable 
cells start to developed a mauve to dark purple colour, the solution is left to incubate for an 
hour to ensure that the assay can work on viable cells, which will remain yellow upon 
addition of MTT. After the incubation period the plates are read using a spectrophotometer, 
using the value obtained for the positive control (inoculated MH broth), a graph can be 
plotted to see at what concentration the cells are no longer viable. 
 
3.10.2 Antifungal screening 
Before antifungal screening could begin, the maximum percentage of DMSO had to be 
determined. Using a similar approach used for antibacterial screening, it was determined 
that a maximum of 5% DMSO could also be used. 
 
Preliminary experiment. 
To determine what concentration of DMSO can be used without affecting the growth of the 
fungi a preliminary test much like the one used for the antibacterial screening had to be 
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employed. Using an agar plate that has a lawn of fungi already grown, pre-soaked disks with 
DMSO concentrations varying from 3-10% (in triplicate) were placed on the plate. The agar 
plates were incubated for a period of 7-10 days, the results were analysed visibly. Fungal 
growth was unaffected up to 5%, after this percentage there was a visible decline in the 
growth of fungi. 
 
3.10.3 Fungi used for testing 
 Aspergillus niger – This fungus was chosen as some Aspergillus species are known to 
cause Aspergillosis. This fungal infection destroys lung tissue and can be fatal 
(Bansod & Rai, 2008). 
 Candida krusei – Candida infections are caused by opportunistic fungi that can result 
in a wide variety of different fungal infections which can be problematic to treat. 
Candida fungal infections can be fatal to patients that are immunocompromised 
(Anaissie, 1992). 
 Mucor – a filamentous fungi which in rare cases can cause aggressive mucormycosis 
infections (Badior, Trigo, Eloy & Guimaraes, 2013). 
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3.10.4 Method fungal sub culturing 
An agar plate with a mature strain of each fungus was provided by the University of 
Hertfordshire. Fresh cultures had to be prepared for antifungal screening. Unlike the 
bacteria, different fungus requires different media. Potato dextrose agar was used for 
Aspergillus niger and Mucor. Malt extract agar was used for Candida krusei. 
For C. krusei the spread plate technique was adopted, spore suspension was prepared and 
50µl of the suspension was spread on the appropriate agar plate. This technique provides a 
thick and evenly distributed lawn of fungi in which any anti-fungal activity could easily be 
seen. The spore suspension was prepared using sterile tap water, as sterile distilled water 
would disrupt the fungal cell wall dues to osmotic pressure. 
 To prepare A. niger and Mucor plates aseptic PDA Petri dishes were prepared. A cork bore 
plug (5mm in diameter) of pre-grown fungi was placed in the middle, the fungi was 
incubated and left to grow until a thick and even lawn of fungal growth was present. To test 
antifungal activity antibiotic disks were used. Five antibiotic disks were used per plate, 1 disk 
was inoculated in pure DMSO, 1 disk was inoculated with a control drug, and 3 disks of the 
same concentration of compound were inoculated. The inoculated disks were placed 
around the fungi plug and the growth monitored daily. 
3.10.5 Results for determination of DMSO percentage 
The following graphs show the results of DMSO on the growth of Bacillus subtilis, 
Escherichia coli, Proteus hauseri and, Staphylococcus aureus. All tests were carried out in 
triplicate, the absorbance values for bacterial growth after 16-18 hours without the 
presence of DMSO was also recorded in triplicate.  
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Figure 15: shows the growth of Bacillus subtilis, Escherichia coli, Proteus hauseri and, 
Staphylococcus aureus in the presence of DMSO (3-10%) after a 16-18 hour incubation 
period. 
Figure 15 shows after the growth of all four bacteria in the presence of DMSO (3-10%).  As 
the concentration of DMSO was increased, the average absorbance values decreased from 
an average wavelength of 0.900 at 3% concentration to an average absorbance value of 
0.100. Figure 15 shows that for Bacillus subtilis, Proteus hauseri and, Staphylococcus aureus 
there is a steep decrease in absorbance after 5% DMSO, which indicates that the DMSO is 
having an inhibitory effect. The absorbance values for Escherichia coli gradually decrease 
after 5%. 
 
3.10.6 Results for Gram staining. 
As expected the gram positive Bacillus subtilis and Staphylococcus aureus retained the 
crystal violet dye and had a purple appearance. The gram negative Escherichia coli and 
Proteus hauseri were decoloured and retained the counter stain appearing pink in colour. 
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3.10.7 Minimum inhibitory concentration of reference antibiotic, streptomycin against all 
four bacteria. 
 
Figure 16: the graph shows the absorbance measured at 590nm after 16-18 hour incubation 
period for Bacillus subtilis, Escherichia coli, Proteus hauseri and, Staphylococcus aureus in at 
different concentrations of streptomycin. 
As shown in figure 16 all the bacteria were inhibited at a concentration of 1 mg ml-1, this 
concentration was used in all antibacterial screening. 
 
3.10.8 Results for antibacterial screening. 
All 18 compounds were screened for antibacterial activity. Compound 27 exerted the most 
noticeable antibacterial effect. Some compounds displayed some activity, at the 
concentration of 6.67 mg ml-1; further testing would be needed to investigate whether this 
concentration is viable. 
The compounds were screened at 8 different concentrations the highest concentration used 
was 6.67 mg ml-1 and the lowest was 52 µg ml-1. 
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Compound concentrations used mg ml-1 
6.67 
3.3 
1.6 
0.833 
0.416 
0.208 
0.104 
0.052 
Table 6: shows the different compound concentrations used. 
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3.10.9 Cytotoxicity studies of compounds 22-39 against Bacillus subtilis Escherichia coli, 
Proteus hauseri and, Staphylococcus aureus. 
 
Figure 17: shows the absorbance of B. subtilis measured at 590nm with compounds 22-30 
after 16-18hrs incubation and the addition of MTT.  
From figure 17 it can be seen that the growth of B. subtilis is inhibited by Compound 27 at 
concentration of 0.833 mg ml-1 and continued to decrease Streptomycin was the reference 
drug at a concentration of 1 mg ml-1. Compounds 22, 23, 24, 25 and 30 displayed inhibition 
at the highest concentration (6.67 mg ml-1) only. 
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Figure 18: shows the absorbance of B. subtilis measured at 590 nm with compounds 31-39 
after 16-18hrs incubation and the addition of MTT.  
From figure 18 it can be seen that the growth of B. subtilis is inhibited by compounds 31, 32, 
33, 34, 35, 38 and 39 at the highest concentration of 6.67 mg ml-1. Compounds 36 and 37 
show no inhibition. Streptomycin was the reference drug at a concentration of 1 mg ml-1. 
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Figure 19: shows the absorbance of E. coli measured at 590 nm with compounds 22-30 after 
16-18hrs incubation and the addition of MTT. 
From figure 19 it can be seen that the growth of E. coli is inhibited by Compound 27 from 
the highest concentration of 6.67 mg ml-1 down to the concentration of 1.6 mg ml-1. From 
the graph it can be seen that concentrations below 1.6 mg ml-1 have a steep decrease in 
inhibitory effect on the growth of E. coli. Streptomycin was the reference drug at a 
concentration of 1 mg ml-1. Compounds 22, 23, 24, 25, 27 and 29 displayed inhibition at the 
highest concentration.  
.  
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Figure 20: shows the absorbance of E. coli measured at 590nm with compounds 31-39 after 
16-18hrs incubation and the addition of MTT. 
From figure 20 it can be seen that the growth of E. coli is inhibited by compounds 31, 32, 33, 
35 and 38 from the highest concentration of 6.67 mg ml-1. For compounds 31, 32, 33 and 35 
there is a steep increase in absorbance values which indicates that after the highest 
concentration the compounds no longer inhibit the growth of E. coli. Streptomycin was the 
reference drug at a concentration of 1 mg ml-1. 
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Figure 21: shows the absorbance of P. hauseri measured at 590nm with compounds 22-30 
after 16-18hrs incubation and the addition of MTT. 
From figure 21 it can be seen that the growth of P. hauseri is inhibited by Compound 27 
from the highest concentration of 6.67 mg ml-1 down to the concentration of 0.833 mg ml-1. 
From the graph it can be seen that concentrations below 0.833 mg ml-1 have a steep 
decrease in inhibitory effect on the growth of P. hauseri. As the concentration falls below 
0.208 mg ml-1 the absorption plateaus this indicates that Compound 27 has no effect on the 
growth of P. hauseri. Streptomycin was the reference drug at a concentration of 1 mg ml-1. 
Compounds 22, 23, 24 and 25 are having an inhibitory effect on the growth of the bacteria 
at the highest concentration. 
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Figure 22: shows the absorbance of P. hauseri measured at 590nm with compounds 31-39 
after 16-18hrs incubation and the addition of MTT. 
From figure 22 it can be seen that the growth of P. hauseri is inhibited by compounds 31, 32, 
33, 34, 35 and 38 at the highest concentration of 6.67 mg ml-1. Compound 31 displayed 
inhibition of growth down to a concentration of 3.3 mg ml-1 but as the concentration 
decreases the inhibition of growth stops. Streptomycin was the reference drug at a 
concentration of 1 mg ml-1  
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Figure 23: shows the absorbance of S. aureus measured at 590nm with compounds 22-30 
after 16-18hrs incubation and the addition of MTT. 
From figure 23 it can be seen that the growth of S. aureus is inhibited by Compound 27 from 
the highest concentration of 6.67 mg ml-1 down to the concentration of 0.833 mg ml-1. From 
the graph it can be seen that concentrations below 0.833 mg ml-1 have a steep decrease in 
inhibitory effect on the growth of S. aureus. As the concentration fall below 0.208 mg ml-1 
the absorption plateaus, this indicates that Compound 27 has no effect on the growth of S. 
aureus. Compounds 22, 23, 25, 26 and 30 displayed some inhibition at the highest 
concentration. Streptomycin was the reference drug at a concentration of 1 mg ml-1  
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Figure 24: shows the absorbance of S. aureus measured at 590nm with compounds 31-39 
after 16-18hrs incubation and the addition of MTT. 
From figure 24 it can be seen that the growth of S. aureus is inhibited by compounds 31, 32, 
33, 37 and 38 at the highest concentration of 6.67 mg ml-1. Streptomycin was the reference 
drug at a concentration of 1 mg ml-1 
 
3.11 Results for antifungal screening 
Two different methods were applied to determine if any of the 18 compounds had any 
antifungal properties, after the compounds were added and the agar plates were left to 
incubate no inhibition of growth was observed which indicated that the benzoisothiazoles 
had no significant antifungal properties. 
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Chapter 4 
4.1 Discussion 
The problems that have arisen due to the emergence of antimicrobial resistance have 
resulted in the desperate need for novel classes of antimicrobial agents. The varieties of 
diseases and bacterial infections that have now become resistance to many gold standard 
drugs have reached a potentially lethal stage. Antibiotic resistance has been the focal point 
of concern for the past decade however less attention has been paid to the development of 
antifungal resistance. A review article of current antifungal agents, published by a research 
group in India has outlined the interest of novel heterocyclic compounds being synthesized 
and screened for antifungal activity (Kathiravan et al., 2012). The biological properties of 
heterocycles that include nitrogen, oxygen and sulphur have been reported extensively over 
the last century although there have been no reports on benzoisothiazoles fused pyrazine 
rings. This has prompted interest into the synthesis and biological screening of the novel 
class of benzoisothiazoles derivatives. 
According to the literature the synthesis and spectral characterization of benzo[4,5] 
isothiazolo[2,3-a]pyrazine-6,6-dioxide derivatives has not been reported previously. The 
present work reports the synthesis and spectral characterisation of the novel ring system 
benzo [4,5]isothiazolo[2,3-a]pyrazine-6,6-dioxide. 
 
     
Figure 25: Structure of 1,3,4,10b-tetrahydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrazine-6,6-
dioxide. 
 
 
63 
 
The compounds were synthesized by reacting a series of dibromo chalcones sulphonyl 
chlorides with 1,2-diaminopropane and 2-methyl-1, 2 diamino-propane respectively. The 
yield of compounds, ranged from 12-80% with compound 33 obtaining a yield of 12% and 
compound 37 with a yield of 80%.  
 
 
 
 
 
 
 
 
Scheme 3: shows the full proposed mechanism for the formation of the benzoisothiazole 
derivative. 
All compounds were recrystallized and spectral analysis conducted on the purified products. 
Thin layer chromatography confirmed purity of compounds; proton and carbon NMR 
spectra confirmed the structures. For all the compounds the infrared spectra indicated the 
presence of the carbonyl group in the region of 1681 cm-1 and 1660 cm-1. Similarly, presence 
of the suphonyl group was confirmed by absorption in the region 1130-1170 and 1330-1350 
cm-1. The expected peak for (-NH) group was observed in the region of 3310-3320 cm-1.  
The definitive structures of the compound were confirmed by the X-ray analysis of 
compound 31. The x-ray structure clearly confirmed that the two methyl groups were on 
the carbon atom next to the NH group (see figure 29). All the compounds were reacted 
under the same reaction conditions. Using NMR data combined with the X-ray data the 
structures for all 18 compounds were correctly elucidated. 
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Figure 26: X-Ray structure of compound 31. 
Table 9:  Crystal data and structure refinement for compound 31. 
 
Identification code  Compound 31 
Empirical formula  C21H24N2O5S 
Formula weight  416.5 
Temperature  171(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1) 
 
Unit cell dimensions a = 5.8645(9) Å α= 90°. 
 b = 19.946(3) Å β= 97.459(3) °. 
 c = 8.8732(14) Å γ = 90°. 
Volume 1029.1(3) Å3 
Z 2 
Density (calculated) 1.402 Mg/m3 
Absorption coefficient 0.199 mm-1 
F(000) 460 
Crystal size 0.30 x 0.19 x 0.08 mm3 
Theta range for data collection 2.04 to 28.30°. 
Index ranges -7<=h<=7, -26<=k<=26, -11<=l<=11 
Reflections collected 11737 
Independent reflections 4948 [R(int) = 0.0394] 
Completeness to theta = 28.30° 98.6 %  
 
  
 
                
 
65 
 
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4948 / 3 / 283 
Goodness-of-fit on F2 0.894 
Final R indices [I>2sigma(I)] R1 = 0.0419, wR2 = 0.0978 
R indices (all data) R1 = 0.0523, wR2 = 0.1053 
Absolute structure parameter 0.04(7) 
Largest diff. peak and hole 0.278 and -0.298 e.Å-3 
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4.2 Biological screening 
All eighteen benzoisothiazoles compounds were screened against four bacteria Bacillus 
subtilis, Escherichia coli, Proteus hauseri and Staphylococcus aureus. The compounds were 
also screened against three fungi Aspergillus niger, Candida krusei and Mucor. Due to 
solubility problems, the precise concentration of each compound interacting with the 
bacterial cells could not be ascertained. Activity was displayed by some compounds and this 
was analysed using MTT assays however no firm statistical data could be obtained. Using 
the MTT reduction assay, rapid and reproducible results were obtained for antibacterial 
screening.  From the literature used many novel compounds that were screened for 
biological activity were done so without a particular mechanism of action in mind. 
4.3 Antibacterial screening 
Antibacterial screening was conducted using the following bacteria Bacillus subtilis, 
Escherichia coli, Staphylococcus aureus and Proteus hauseri. 20 mg of the compound was 
dissolved in 1 ml of pure DMSO to prepare stock solutions of 20 mg ml-1. Initial screening 
started with 6.67 mg ml-1 and was diluted down to 0.1 mg ml-1 (104 µg ml-1) in a 96 well 
plate. Due to solubility issues the stock solutions could not be diluted with distilled water, 
therefore the compound solution was diluted down in concentration using the culture 
inoculated broth. Initial tests showed that a maximum concentration of 5% DMSO could be 
used and had no cytotoxic effect on the four types of bacteria. To improve solubility of the 
compounds the 96 well plates were incubated on a rotary shaker. The rotary shaker 
improved the solubility of the compounds it was noticed that there was less precipitate 
present after the incubation period; however this was only noticed at concentrations below 
3 mg ml-1  
The concentration of the compounds was tested in a range of 6.67 mg ml-1 down to 104 mg 
ml-1. Dilutions were carried out so that each well had 50 µl of medium with a particular 
concentration of compound. An equal volume of fixed bacterial culture was added to the 
wells and incubated at 37oC for 16-18 hours. The inoculums was adjusted to 0.5 McFarland 
turbidity standard (Ncube, Afolayan, & Okoh, 2008).  Streptomycin was used as a reference 
drug throughout all the antibacterial testing.  
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Using MTT assay as an activity detection method is less conventional than the more 
commonly used disk diffusion assay. As the MTT assay was used as a preliminary 
investigation to ensure a more accurate set of results a method of using disk diffusion 
should be used to determine a narrower range of concentration at which the compound is 
active. 
Compound 27 displayed promising antibacterial activity against all four bacteria at 
concentrations of 6.67 mg ml-1 down to 104 mg ml-1. Compound 27 exerted the most 
activity against B. subtilis. Inhibition was observed from a concentration of 0.416 mg ml-1, 
from the MTT assay it can be seen that compound was as effective as the control drug 
streptomycin at the concentration of 0.4 mg ml-1. 
Compound 27 inhibited the growth of both E. coli and S. aureus at a concentration of 1.6 mg 
ml-1. As the concentration of Compound 27 decreased from 1.6 mg ml-1 down to the lowest 
concentration of 0.052 mg ml-1 the inhibitory effect of the compound decreased rapidly. 
Compound 27 had the least antibacterial activity against P. Hauseri; inhibition was displayed 
at the highest concentration of Compound 27 this indicates that the compounds are less 
potent against gram-negative bacteria. Streptomycin is bactericidal, which indicates that the 
benzoisothiazoles derivates that had antibacterial activity in higher concentration had 
bactericidal activity. As the concentration and inhibition decreased the compounds appear 
to be bacteriostatic. 
From the antibacterial screening it was observed that Compound 27 was the most active 
against gram positive bacteria. This indicates that a chlorine atom in the meta position on 
the benzene ring is structurally significant. Compound 27 had one methyl group present on 
the fused pyrazine ring. There was no visible trend or similarity in results that correlated to 
the number of methyl groups on the pyrazine ring. There was no visible correlation between 
activity and halogen present; however there is much evidence in the literature to support 
the potency enhancing effects of halogen substituents. A research group in India 
synthesised a novel library of benzimidazole-oxadiazole derivatives with aim of developing 
newer and more potent antimicrobial agents. The research conducted stated that 
benzothiazole templates are important lead compounds in the design of pharmacologically 
active heterocycles (Patel, Patel, Kumari, Rajani, & Chikhalia, 2012) from the biological 
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screening it was concluded that the novel compounds bearing a benzothiazole ring were 
active against all the pathogenic strains tested and found that the benzothiazole rings that 
were attached to an electron withdrawing halogen had the highest potency (Patel et al., 
2012). The position of the chlorine atom is structurally significant. When comparing 
Compound 27 to established fused heterocyclic antibacterial agents it can be noted that this 
compound has structural similarities to a variety of antibacterial agents such as the 
sulphone group which is common in some sulphonamide antibiotics. Another structural s 
similarity is the presence of a five membered ring which contains electronegative atoms 
which is found in carbapenem antibiotics, although the mechanism of action for the 
synthesized compounds would need to be validated before any strong correlation between 
structures could be ascertained.  
Heterocyclic systems containing nitrogen, sulphur and oxygen atoms are essential building 
blocks in chemistry and fundamental to life. From what is available in the literature 
antimicrobial agents more often than not contain at least one or more of these three 
elements. The addition of halogens are frequently employed to increase antimicrobial 
activity, however with the exception of compound 27, there was no significant difference in 
activity when varying the substituent group. 
Research conducted by Rani and co-workers has shown that nitrogen and sulphur bicyclic 
thiadiazoles derivatives containing the electron withdrawing group fluorine displayed 
excellent antimicrobial properties against E. coli, S. aureus, A. niger and C .albicans. This 
research found a trend in activity with fluorine being the most active substituent followed 
by chlorine, methyl then methoxy groups. Antimicrobial activity was observed at 
concentrations of 6.25-100 µg ml-1. Compounds that contained a methoxy group had 
significantly less activity against the bacteria and fungi tested (Rani, Ramachandran and 
Kabilan, 2010). This could possibly indicate that the presence of a methoxy group reduces 
the antimicrobial activity of a compound. 
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Azo dyes have recently attracted interest as potential antimicrobial agents. A library of novel 
heterocyclic disazo dyes were synthesised and screened for antimicrobial activity. Although 
no antibacterial activity was observed, two novel azo dye compounds displayed potent 
antifungal activity with a chlorine substituent group with antifungal activity more potent 
than that of the control drug fluconazole (Karci, Şener, Yamaϛ, Demirϛal, 2009).  
Fluoroquinolones (FQs) are still noted for their antibacterial effectiveness, this is due to the 
drugs ability to inhibit two essential bacterial enzymes. Research and development into this 
group of drugs is continually being conducted as FQs are a broad spectrum antibiotic. A 
review article by Bush & Pucci has discussed a novel group of DNA topoisomerase inhibitors 
all containing a fluoroquinolone moiety with excellent antibacterial activity against 
Staphylococcus aureus (Bush & Pucci, 2012). An interesting area of research to pursue 
would be to introduce a quinolone structure onto the benzoisothiazole derivatives, this 
could lead to a more potent set of compounds. 
The library of compounds synthesized were found to be more active on gram positive 
bacteria. This suggests that the mechanism of action could be cell wall synthesis inhibition; 
although for this to be validated further investigation would be required.  Calculated log P 
values of 1.51-1.73 were obtained which indicates the compounds were lipophilic enough to 
penetrate the cell wall of gram positive bacteria, which is lipophilic in nature. For further 
research into the antimicrobial properties of this group of benzoisothiazoles derivatives, it is 
necessary for more work to be conducted on improving the solubility of these compounds.  
 
4.4 Antifungal screening 
Like the antibacterial screening, initial testing for DMSO fungal toxicity needed to be 
investigated. A range of different DMSO concentrations were tested, a maximum of 5% 
DMSO was tolerated by the fungi. The 3 fungi screened were Aspergillus niger, Candida 
krusei and Mucor. 70 µl of the compound mixture was absorbed onto antibiotic disks the 
disks were then placed on an agar plate that had an evenly distributed lawn of fungal 
growth. The agar plates were left to further grow to see if the compounds had any 
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fungicidal or fungiostatic activity. The growth activity of the fungi was monitored at 24hr 
intervals.  
Although the compounds synthesized contained an azole moiety there was no antifungal 
activity exhibited by any of the compounds. This could be due to the presence of a SO2 
group in the benzoisothiazole ring. The majority of the azole based antifungals contain 
halogens but no sulphur atoms; this indicates that the presence of a SO2 decreases 
antifungal activity. 
In a study conducted by Koparir and co-workers a novel library of 1,2,4-triazole derivatives 
were synthesized and screened for antibacterial activity against E. coli, S. aureus, K. 
pneumoniae and P. aeruginosa and antifungal activity against two strains of Aspergillus. The 
compounds that bore a hydroxyl group on the phenyl ring attached to the triazole ring 
displayed potent antibacterial activity at a concentration of 6.25µgml-1 against E. coli and S. 
aureus and similar results for Aspergillus flavus (Koparir, Orek, Koparir & Sarac, 2012). From 
this it can be deduced that triazole rings fused to phenol rings are structurally significant, in 
comparison to the compounds synthesized in the current research a possible way to 
increase the antifungal activity of these compounds would be to incorporate a triazole ring. 
A series of novel benzimidazole derivatives were synthesized by Desai and co-workers in 
2013. These compounds have displayed excellent antifungal properties, one compound in 
particular showed a fungal MIC that was lower than the standard antifungal drugs 
chloramphenicol and ketoconazole that were used in the tests (Desai, Shihory & Kotadiya, 
2013). A significant finding of this research was that compounds that contained fluoro or 
nitro electron withdrawing groups displayed the most potent activity.  
Compounds 22-39 all contained two methoxy groups which are electron donating groups 
(EDGs), from the literature available there is a significant amount of evidence showing that 
the presence of an electron donating group limits the potential antimicrobial activity of a 
compound. To improve both potential activity and solubility of the compounds it would be 
beneficial to substitute the two methoxy groups, to groups that have stronger electron 
withdrawing capabilities. 
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Chapter 5 
5.1 Conclusion 
In summary, the study conducted in the work has designed a new synthetic route to 
benzoisothiazole derivatives, from readily available starting materials. The compounds 
synthesized showed potential biological activity against gram positive bacteria B. subtilis and 
P. hauseri. Due to insolubility of the compounds in DMSO future work would involve the 
incorporation of hydroxyl groups or an added ring structure. Another possible line of 
investigation could be to synthesize the amine salt of the benzoisothiazoles.  
As a preliminary experiment, MTT assay was employed, additional work to validate the 
antimicrobial properties of these compounds would include disk diffusion assays and 
determination of minimal inhibitory concentration (MIC) however the solubility issues 
would need to be resolved first. 
 
5.2 Future work 
The first avenue of work would be to increase the solubility of the 18 compounds, a possible 
route for this would be to convert the two methoxy groups on the 1,2-dimentoxybenzene 
ring to hydroxyl, in a method described by Alonso et al two methoxy groups were 
demethylated to produce two hydroxyl groups. Methylated resveratrol was refluxed at 0oC 
for 5 hours in a mixture of Boron tribromide (BBr3) and chloroform; this gave a yield of 70% 
for the demethylated final product (Alonso, Riente & Yus 2009). 
If all the compounds are successfully demethylated and solubilities enhanced then possible 
re-screening for activity could be an option, and could potentially lead to more potent set of 
compounds which could be further modified to produce a larger library of compounds. From 
this, a more in-depth investigation of biological activity could be achieved, with possible 
statistical analysis being employed. 
Other routes to pursue would be introducing another ring to the core structure or possibly 
making an amine salt. 
 
72 
 
 
 
 
 
 
Figure 27: (8,9-Dimethoxy-3-methyl-6,6-dioxido-2,3,4,10b-tetrahydro-1Hbenzo[4,5] 
isothiazolo[2,3-a]pyrazin-1-yl)(3-chlorophenyl)methanone 27. 
Compound 27 see Figure 27, displayed promising activity against B. subtilis and some 
activity against the other 3 bacteria. Compound 27 could either be further tested for any 
possible biological importance such as anti-tuberculosis and possibly anti-inflammatory 
activity solubility permitting. If Compound 27 was structurally modified and solubility 
increased then it could possibly be reassessed via in silico methods. To fully explore the idea 
of a QSAR model it would be ideal to have between 20-30 analogues of compounds 27 
which is another area of work that could be investigated. 
Structure activity relationships (SARs) provide a correlation between chemical structure and 
biological activity whilst being reinforced with statistical analysis. To further enhance the 
antimicrobial properties of this class of compounds it would be useful to develop a SAR 
model by collecting data on the 3D structure of known antimicrobial agents and their 
biological activity (McKinney, Richard, Waller, Newman & Gerbericks, 2000). 
From the available literature, benzoisothiazoles are an essential starting point for 
pharmaceutically active compounds. Benzoisothiazoles as single units do not appear to 
show much biological importance, however when fused to other heterocyclic ring systems, 
these derivatives display a broad spectrum of activity. The aim of this project is to fuse 
benzoisothiazoles to quinoxalines, benzodiazepines and diazocines to produce a library of 
novel benzoisothiazole derivatives that hopefully display promising biological properties. 
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Using the literature data and synthetic routes available we plan to fuse the benzoisothiazole 
ring to known pharmaceutically active heterocycles i.e. quinoxalines, benzodiazepines and 
diazocines. 
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Appendix III 
Table i.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for compound  31.   
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
 x y z U(eq) 
S(1) 260(1) 4525(1) 4207(1) 19(1) 
N(1) -1286(3) 4472(1) 5593(2) 24(1) 
N(2) -3581(4) 4271(1) 8097(2) 22(1) 
O(1) -871(3) 4889(1) 2912(2) 30(1) 
O(2) 2508(3) 4773(1) 4770(2) 29(1) 
O(3) 2077(3) 2198(1) 1904(2) 29(1) 
O(4) -1094(3) 1656(1) 3240(2) 29(1) 
O(5) -6807(3) 3350(1) 7124(2) 28(1) 
C(1) 124(4) 3663(1) 3872(3) 20(1) 
C(2) 1398(4) 3307(1) 2911(3) 22(1) 
C(3) 958(4) 2624(1) 2747(3) 23(1) 
C(4) -782(4) 2322(1) 3495(3) 22(1) 
C(5) -2039(4) 2700(1) 4406(3) 22(1) 
C(6) -1569(4) 3378(1) 4618(3) 18(1) 
C(7) -2752(4) 3871(1) 5551(3) 20(1) 
C(8) -2006(4) 5066(1) 6367(3) 22(1) 
C(9) -2094(4) 4875(1) 8034(3) 22(1) 
C(10) -2915(4) 3686(1) 7241(3) 20(1) 
C(11) -4816(4) 3161(1) 7311(3) 20(1) 
C(12) -4258(4) 2439(1) 7605(3) 21(1) 
C(13) -2147(5) 2215(1) 8322(3) 30(1) 
C(14) -1770(6) 1538(2) 8607(4) 39(1) 
C(15) -3484(5) 1077(1) 8153(3) 37(1) 
C(16) -5602(5) 1293(1) 7438(3) 32(1) 
C(17) -5998(5) 1963(1) 7170(3) 26(1) 
C(18) 3689(5) 2486(1) 1012(3) 30(1) 
C(19) -2774(5) 1339(1) 4041(3) 32(1) 
C(20) 297(4) 4725(1) 8852(3) 31(1) 
C(21) -3180(5) 5447(1) 8839(3) 29(1) 
O(1W) -4746(4) 4118(1) 1223(3) 51(1) 
 
 
 
 
 
 
4 
 
Table ii.Bond lengths [Å] and angles [°] for 31. 
S(1)-O(2)  1.4353(18) 
S(1)-O(1)  1.4449(18) 
S(1)-N(1)  1.6232(19) 
S(1)-C(1)  1.747(2) 
N(1)-C(8)  1.460(3) 
N(1)-C(7)  1.473(3) 
N(2)-C(10)  1.472(3) 
N(2)-C(9)  1.492(3) 
N(2)-H(1N2)  0.75(3) 
O(3)-C(3)  1.357(3) 
O(3)-C(18)  1.430(3) 
O(4)-C(4)  1.356(3) 
O(4)-C(19)  1.434(3) 
O(5)-C(11)  1.217(3) 
C(1)-C(6)  1.385(3) 
C(1)-C(2)  1.398(3) 
C(2)-C(3)  1.391(3) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.421(3) 
C(4)-C(5)  1.386(3) 
C(5)-C(6)  1.388(3) 
C(5)-H(5)  0.9500 
C(6)-C(7)  1.511(3) 
C(7)-C(10)  1.559(3) 
C(7)-H(7)  1.0000 
C(8)-C(9)  1.536(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(20)  1.523(3) 
C(9)-C(21)  1.528(3) 
C(10)-C(11)  1.536(3) 
C(10)-H(10)  1.0000 
C(11)-C(12)  1.493(3) 
C(12)-C(13)  1.390(4) 
C(12)-C(17)  1.410(3) 
C(13)-C(14)  1.386(4) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.384(4) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.388(4) 
C(15)-H(15)  0.9500 
C(16)-C(17)  1.372(4) 
C(16)-H(16)  0.9500 
C(17)-H(17)  0.9500 
C(18)-H(18A)  0.9800 
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C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(19)-H(19A)  0.9800 
C(19)-H(19B)  0.9800 
C(19)-H(19C)  0.9800 
C(20)-H(20A)  0.9800 
C(20)-H(20B)  0.9800 
C(20)-H(20C)  0.9800 
C(21)-H(21A)  0.9800 
C(21)-H(21B)  0.9800 
C(21)-H(21C)  0.9800 
O(1W)-H(1W)  0.83(3) 
O(1W)-H(2W)  0.88(3) 
 
O(2)-S(1)-O(1) 114.24(11) 
O(2)-S(1)-N(1) 109.70(11) 
O(1)-S(1)-N(1) 113.03(11) 
O(2)-S(1)-C(1) 114.69(11) 
O(1)-S(1)-C(1) 110.66(11) 
N(1)-S(1)-C(1) 92.67(11) 
C(8)-N(1)-C(7) 118.01(18) 
C(8)-N(1)-S(1) 121.80(16) 
C(7)-N(1)-S(1) 114.58(15) 
C(10)-N(2)-C(9) 115.20(18) 
C(10)-N(2)-H(1N2) 110(2) 
C(9)-N(2)-H(1N2) 106(2) 
C(3)-O(3)-C(18) 117.08(19) 
C(4)-O(4)-C(19) 115.83(19) 
C(6)-C(1)-C(2) 123.9(2) 
C(6)-C(1)-S(1) 110.02(17) 
C(2)-C(1)-S(1) 125.98(18) 
C(3)-C(2)-C(1) 117.0(2) 
C(3)-C(2)-H(2) 121.5 
C(1)-C(2)-H(2) 121.5 
O(3)-C(3)-C(2) 125.1(2) 
O(3)-C(3)-C(4) 114.8(2) 
C(2)-C(3)-C(4) 120.1(2) 
O(4)-C(4)-C(5) 124.1(2) 
O(4)-C(4)-C(3) 115.3(2) 
C(5)-C(4)-C(3) 120.6(2) 
C(4)-C(5)-C(6) 119.9(2) 
C(4)-C(5)-H(5) 120.1 
C(6)-C(5)-H(5) 120.1 
C(1)-C(6)-C(5) 118.5(2) 
C(1)-C(6)-C(7) 113.9(2) 
C(5)-C(6)-C(7) 127.6(2) 
N(1)-C(7)-C(6) 103.60(18) 
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N(1)-C(7)-C(10) 106.06(18) 
C(6)-C(7)-C(10) 117.59(19) 
N(1)-C(7)-H(7) 109.7 
C(6)-C(7)-H(7) 109.7 
C(10)-C(7)-H(7) 109.7 
N(1)-C(8)-C(9) 107.41(18) 
N(1)-C(8)-H(8A) 110.2 
C(9)-C(8)-H(8A) 110.2 
N(1)-C(8)-H(8B) 110.2 
C(9)-C(8)-H(8B) 110.2 
H(8A)-C(8)-H(8B) 108.5 
N(2)-C(9)-C(20) 109.3(2) 
N(2)-C(9)-C(21) 107.77(19) 
C(20)-C(9)-C(21) 109.8(2) 
N(2)-C(9)-C(8) 109.22(19) 
C(20)-C(9)-C(8) 111.3(2) 
C(21)-C(9)-C(8) 109.4(2) 
N(2)-C(10)-C(11) 106.05(18) 
N(2)-C(10)-C(7) 111.24(18) 
C(11)-C(10)-C(7) 109.62(19) 
N(2)-C(10)-H(10) 110.0 
C(11)-C(10)-H(10) 110.0 
C(7)-C(10)-H(10) 110.0 
O(5)-C(11)-C(12) 120.4(2) 
O(5)-C(11)-C(10) 118.2(2) 
C(12)-C(11)-C(10) 121.4(2) 
C(13)-C(12)-C(17) 118.6(2) 
C(13)-C(12)-C(11) 123.5(2) 
C(17)-C(12)-C(11) 117.9(2) 
C(14)-C(13)-C(12) 120.6(3) 
C(14)-C(13)-H(13) 119.7 
C(12)-C(13)-H(13) 119.7 
C(15)-C(14)-C(13) 120.1(3) 
C(15)-C(14)-H(14) 119.9 
C(13)-C(14)-H(14) 119.9 
C(14)-C(15)-C(16) 120.0(3) 
C(14)-C(15)-H(15) 120.0 
C(16)-C(15)-H(15) 120.0 
C(17)-C(16)-C(15) 120.2(3) 
C(17)-C(16)-H(16) 119.9 
C(15)-C(16)-H(16) 119.9 
C(16)-C(17)-C(12) 120.6(3) 
C(16)-C(17)-H(17) 119.7 
C(12)-C(17)-H(17) 119.7 
O(3)-C(18)-H(18A) 109.5 
O(3)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
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O(3)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
O(4)-C(19)-H(19A) 109.5 
O(4)-C(19)-H(19B) 109.5 
H(19A)-C(19)-H(19B) 109.5 
O(4)-C(19)-H(19C) 109.5 
H(19A)-C(19)-H(19C) 109.5 
H(19B)-C(19)-H(19C) 109.5 
C(9)-C(20)-H(20A) 109.5 
C(9)-C(20)-H(20B) 109.5 
H(20A)-C(20)-H(20B) 109.5 
C(9)-C(20)-H(20C) 109.5 
H(20A)-C(20)-H(20C) 109.5 
H(20B)-C(20)-H(20C) 109.5 
C(9)-C(21)-H(21A) 109.5 
C(9)-C(21)-H(21B) 109.5 
H(21A)-C(21)-H(21B) 109.5 
C(9)-C(21)-H(21C) 109.5 
H(21A)-C(21)-H(21C) 109.5 
H(21B)-C(21)-H(21C) 109.5 
H(1W)-O(1W)-H(2W) 97(4) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
 
 
 
 
 
 
 
Table iii.   Anisotropic displacement parameters  (Å2x 103) for compound 31.  The 
anisotropic 
displacement factor exponent takes the form:  - 2[ h2 a*2U11+ 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
S(1) 20(1)  16(1) 22(1)  0(1) 6(1)  0(1) 
N(1) 31(1)  18(1) 27(1)  -5(1) 16(1)  -5(1) 
N(2) 21(1)  22(1) 24(1)  -3(1) 7(1)  0(1) 
8 
 
O(1) 40(1)  23(1) 26(1)  4(1) 4(1)  3(1) 
O(2) 20(1)  23(1) 43(1)  -5(1) 4(1)  -3(1) 
O(3) 36(1)  21(1) 35(1)  -5(1) 20(1)  0(1) 
O(4) 37(1)  17(1) 36(1)  -4(1) 17(1)  -3(1) 
O(5) 18(1)  24(1) 41(1)  2(1) 6(1)  0(1) 
C(1) 22(1)  15(1) 23(1)  -2(1) 3(1)  -1(1) 
C(2) 24(1)  20(1) 22(1)  -1(1) 8(1)  -2(1) 
C(3) 26(1)  22(1) 20(1)  -2(1) 7(1)  2(1) 
C(4) 28(1)  17(1) 22(1)  -1(1) 3(1)  0(1) 
C(5) 22(1)  20(1) 24(1)  -2(1) 7(1)  -4(1) 
C(6) 20(1)  18(1) 17(1)  0(1) 4(1)  2(1) 
C(7) 21(1)  17(1) 24(1)  -2(1) 6(1)  -1(1) 
C(8) 24(1)  17(1) 26(1)  -5(1) 8(1)  -1(1) 
C(9) 21(1)  21(1) 26(1)  -4(1) 9(1)  -2(1) 
C(10) 20(1)  19(1) 21(1)  -2(1) 6(1)  -1(1) 
C(11) 21(1)  21(1) 20(1)  0(1) 5(1)  -2(1) 
C(12) 24(1)  22(1) 20(1)  0(1) 8(1)  -2(1) 
C(13) 26(1)  27(1) 35(1)  7(1) 3(1)  -1(1) 
C(14) 41(2)  32(2) 45(2)  11(1) 6(1)  8(1) 
C(15) 48(2)  22(1) 43(2)  9(1) 18(1)  5(1) 
C(16) 40(2)  25(1) 34(1)  -1(1) 13(1)  -7(1) 
C(17) 27(1)  25(1) 28(1)  0(1) 8(1)  -3(1) 
C(18) 32(1)  33(1) 28(1)  -3(1) 15(1)  0(1) 
C(19) 35(2)  19(1) 45(2)  0(1) 16(1)  -4(1) 
C(20) 22(1)  35(1) 34(1)  -5(1) 3(1)  -4(1) 
C(21) 35(1)  24(1) 31(1)  -7(1) 12(1)  -1(1) 
O(1W) 51(1)  72(2) 30(1)  8(1) 6(1)  -29(1) 
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Table iv.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for compound 31. 
 x y  z  U(eq) 
H(2) 2514 3522 2392 26 
H(5) -3220 2496 4884 26 
H(7) -4319 3977 5018 24 
H(8A) -3541 5216 5888 26 
H(8B) -898 5436 6302 26 
H(10) -1409 3505 7729 24 
H(13) -954 2528 8620 35 
H(14) -331 1390 9114 47 
H(15) -3211 612 8330 44 
H(16) -6781 976 7133 39 
H(17) -7456 2108 6688 32 
H(18A) 4392 2130 466 45 
H(18B) 4888 2723 1679 45 
H(18C) 2892 2802 279 45 
H(19A) -2869 861 3782 48 
H(19B) -4277 1550 3751 48 
H(19C) -2325 1390 5138 48 
H(20A) 187 4606 9912 46 
H(20B) 1274 5122 8821 46 
H(20C) 969 4350 8349 46 
H(21A) -4708 5547 8300 44 
H(21B) -2207 5847 8845 44 
H(21C) -3319 5315 9887 44 
H(1W) -4250(80) 4180(30) 400(40) 95(17) 
H(2W) -3700(60) 4360(20) 1790(40) 73(13) 
H(1N2) -4770(50) 4381(15) 7780(30) 24(8) 
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Table v. Torsion angles [°] for compound 31. 
O(2)-S(1)-N(1)-C(8) 67.0(2) 
O(1)-S(1)-N(1)-C(8) -61.7(2) 
C(1)-S(1)-N(1)-C(8) -175.51(19) 
O(2)-S(1)-N(1)-C(7) -139.92(17) 
O(1)-S(1)-N(1)-C(7) 91.33(18) 
C(1)-S(1)-N(1)-C(7) -22.48(18) 
O(2)-S(1)-C(1)-C(6) 127.07(17) 
O(1)-S(1)-C(1)-C(6) -101.91(18) 
N(1)-S(1)-C(1)-C(6) 13.94(18) 
O(2)-S(1)-C(1)-C(2) -57.2(2) 
O(1)-S(1)-C(1)-C(2) 73.8(2) 
N(1)-S(1)-C(1)-C(2) -170.3(2) 
C(6)-C(1)-C(2)-C(3) -2.0(4) 
S(1)-C(1)-C(2)-C(3) -177.14(19) 
C(18)-O(3)-C(3)-C(2) -5.8(4) 
C(18)-O(3)-C(3)-C(4) 174.1(2) 
C(1)-C(2)-C(3)-O(3) -177.8(2) 
C(1)-C(2)-C(3)-C(4) 2.3(3) 
C(19)-O(4)-C(4)-C(5) -2.9(3) 
C(19)-O(4)-C(4)-C(3) 177.3(2) 
O(3)-C(3)-C(4)-O(4) -0.9(3) 
C(2)-C(3)-C(4)-O(4) 179.0(2) 
O(3)-C(3)-C(4)-C(5) 179.3(2) 
C(2)-C(3)-C(4)-C(5) -0.7(4) 
O(4)-C(4)-C(5)-C(6) 179.0(2) 
C(3)-C(4)-C(5)-C(6) -1.3(4) 
C(2)-C(1)-C(6)-C(5) 0.0(4) 
S(1)-C(1)-C(6)-C(5) 175.83(19) 
C(2)-C(1)-C(6)-C(7) -178.1(2) 
S(1)-C(1)-C(6)-C(7) -2.3(2) 
C(4)-C(5)-C(6)-C(1) 1.7(3) 
C(4)-C(5)-C(6)-C(7) 179.5(2) 
C(8)-N(1)-C(7)-C(6) 177.43(18) 
S(1)-N(1)-C(7)-C(6) 23.3(2) 
C(8)-N(1)-C(7)-C(10) -58.1(3) 
S(1)-N(1)-C(7)-C(10) 147.74(15) 
C(1)-C(6)-C(7)-N(1) -12.1(3) 
C(5)-C(6)-C(7)-N(1) 170.0(2) 
C(1)-C(6)-C(7)-C(10) -128.7(2) 
C(5)-C(6)-C(7)-C(10) 53.4(3) 
C(7)-N(1)-C(8)-C(9) 60.8(3) 
S(1)-N(1)-C(8)-C(9) -147.06(17) 
C(10)-N(2)-C(9)-C(20) -66.5(3) 
C(10)-N(2)-C(9)-C(21) 174.2(2) 
C(10)-N(2)-C(9)-C(8) 55.5(3) 
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N(1)-C(8)-C(9)-N(2) -53.9(2) 
N(1)-C(8)-C(9)-C(20) 66.9(2) 
N(1)-C(8)-C(9)-C(21) -171.64(19) 
C(9)-N(2)-C(10)-C(11) -173.64(19) 
C(9)-N(2)-C(10)-C(7) -54.5(3) 
N(1)-C(7)-C(10)-N(2) 50.8(2) 
C(6)-C(7)-C(10)-N(2) 166.10(19) 
N(1)-C(7)-C(10)-C(11) 167.82(18) 
C(6)-C(7)-C(10)-C(11) 
Appendix IV 
Table of absorbance readings at 590nm for Bacillus subtilis after adding MTT 
[mg ml-1] Compounds  
 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Ctrl 
0.052 
 1.191 1.597 1.37 1.181 1.073 1.529 1.038 1.189 1.279 1.514 1.15 1.207 1.126 1.629 1.611 1.717 1.658 1.357 0.05 
0.104 1.195 1.72 1.341 1.192 1.049 1.488 1.003 1.185 1.279 1.715 1.215 1.209 1.132 1.602 1.66 1.75 1.599 1.391 0.05 
0.208 1.189 1.735 1.289 1.148 1.032 1.602 0.972 1.194 1.256 1.712 1.206 1.174 1.116 1.583 1.625 1.717 1.615 1.388 0.05 
0.416 1.189 1.635 1.289 1.145 1.020 1.255 0.926 1.156 1.281 1.6448 1.223 1.214 1.155 1.602 1.562 1.715 1.555 1.329 0.05 
0.833 1.159 1.462 1.239 1.155 0.972 0.237 0.887 1.128 1.292 1.544 1.183 1.219 1.194 1.701 1.348 1.71 1.216 1.338 0.05 
1.6 1.158 1.345 1.342 1.116 0.964 0.139 1.008 1.173 1.338 1.519 1.149 1.173 1.215 1.567 1.649 1.872 1.171 1.412 0.05 
3.3 1.359 1.441 1.188 1.150 1.149 0.117 1.289 1.114 1.39 1.742 1.132 1.451 1.606 1.301 1.388 1.436 0.945 1.433 0.05 
6.67 0.852 0.318 0.218 0.635 0.680 0.087 1.116 1.180 0.775 0.660 0.351 0.683 0.278 0.214 1.472 1.556 0.279 0.929 0.05 
[mg ml-1] = Concentration of compound in mg ml-1
 
Ctrl = Control is the reference drug streptomycin 
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Table of absorbance readings at 590 nm in natural log for Bacillus subtilis after adding MTT 
 
22 23 24 25 26 27 28 29 30 
0.052 3.29036993 4.93819559 3.9353507 3.2576302 2.92413877 4.61356095 2.82356423 3.28379577 3.593044884 
0.104 3.30355777 5.58452846 3.82286446 3.29366195 2.8547949 4.4282302 2.72644892 3.27068682 3.593044884 
0.208 3.28379577 5.6689278 3.62915558 3.15188284 2.80667357 4.9629484 2.64322563 3.30025586 3.511347967 
0.416 3.28379577 5.129458 3.62915558 3.14244136 2.77319476 3.50783837 2.52439139 3.17719903 3.600238164 
0.833 3.18674494 4.31458007 3.45215958 3.17402342 2.64322563 1.26744112 2.42783521 3.08947137 3.640059399 
1.6 3.18355979 3.83818654 3.82668924 3.05261927 2.62216418 1.1491241 2.7401153 3.23167313 3.811413051 
3.3 3.89229906 4.22491862 3.28051361 3.15819291 3.1550363 1.12411943 3.62915558 3.04652014 4.014850053 
6.67 2.34433083 1.37437626 1.24358707 1.88702214 1.97387773 1.09089668 3.05261927 3.2543742 2.170592127 
 
 
31 32 33 34 35 36 37 38 39 
0.052 4.54487398 3.15819291 3.34343927 3.08329861 5.09877339 5.00781654 5.56779998 5.24880273 3.884522237 
0.104 5.55667551 3.37029406 3.35013284 3.10185401 4.9629484 5.25931084 5.75460268 4.94808187 4.018866911 
0.208 5.54003047 3.34009751 3.23490642 3.05261927 4.86954255 5.07841904 5.56779998 5.02788792 4.006828377 
0.416 5.11920933 3.39736455 3.36692545 3.17402342 4.9629484 4.76834841 5.55667551 4.73508653 3.777264234 
0.833 4.683286 3.26415198 3.38380224 3.30025586 5.47942408 3.84971839 5.52896148 3.37366604 3.811413051 
1.6 4.56765526 3.1550363 3.23167313 3.37029406 4.79224986 3.85357003 6.50128598 3.22521624 4.104155512 
3.3 5.70874951 3.10185401 4.26737976 4.98283995 3.6729678 4.00682838 4.20384675 2.57281338 4.191254112 
6.67 1.93479233 1.42048733 1.97980826 1.3204862 1.23862265 4.35794232 4.73982398 1.32180734 2.531975935 
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Table of absorbance readings at 590nm for Escherichia coli after adding MTT 
[mg ml-1] = Concentration of compound in mg ml-1
 
Ctrl = Control is the reference drug streptomycin 
 
[mg ml-
1] 
Compounds  
 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Ctrl 
0.052 1.218 1.385 1.026 1.356 1.687 1.855 1.395 1.221 1.341 1.587 1.393 1.908 1.599 1.382 1.353 1.212 1.658 1.352 0.050 
0.104 1.212 1.387 1.122 1.391 1.674 1.636 1.524 1.171 1.355 1.593 1.452 1.899 1.581 1.47 1.301 1.205 1.571 1.388 0.050 
0.208 1.221 1.391 1.134 1.375 1.607 1.541 1.485 1.103 1.301 1.559 1.355 1.717 1.565 1.298 1.258 1.17 1.587 1.368 0.050 
0.416 1.214 1.425 1.153 1.343 1.605 1.555 1.737 1.125 1.305 1.453 1.358 1.702 1.568 1.286 1.213 1.146 1.613 1.427 0.050 
0.833 1.246 1.401 1.306 1.338 1.598 1.312 1.746 1.135 1.289 1.579 1.331 1.714 1.606 1.305 1.084 1.222 1.568 1.401 0.050 
1.6 1.378 1.106 1.242 1.412 1.458 0.148 1.822 1.651 1.21 1.479 1.293 1.688 1.72 1.446 1.141 1.304 1.432 1.525 0.050 
3.3 1.415 1.078 1.203 1.433 1.063 0.130 1.757 1.721 1.135 1.025 1.387 1.436 1.732 1.336 0.837 1.634 1.331 1.857 0.050 
6.67 0.711 0.954 0.725 0.929 1.311 0.154 0.894 1.765 0.261 0.774 0.613 1.556 0.388 0.614 1.588 1.657 0.354 1.392 0.050 
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Table of absorbance readings at 590 nm in natural log for Escherichia coli after adding MTT 
 
 
22 23 24 25 26 27 28 29 30 
0.052 3.38042013 3.9948259 2.78988395 3.88063966 5.40324663 6.39169825 4.03497457 3.39057662 3.822864459 
0.104 3.36019833 4.00282355 3.07099005 4.01886691 5.33345902 5.13459002 4.59055072 3.22521624 3.876760957 
0.208 3.39057662 4.01886691 3.10806392 3.95507672 4.98782528 4.66925719 4.41496541 3.01319205 3.6729678 
0.416 3.36692545 4.15785784 3.16768171 3.83051784 4.9778596 4.73508653 5.680277 3.08021685 3.687689094 
0.833 3.47640947 4.0592572 3.69137863 3.81141305 4.94313626 3.71359348 5.73163024 3.11117354 3.629155585 
1.6 3.96695977 3.0222452 3.46253161 4.10415551 4.29735622 1.1595129 6.18421452 5.21218941 3.353484653 
3.3 4.11648647 2.93879608 3.33009223 4.19125411 2.8950431 1.13882838 5.79502621 5.59011579 3.111173543 
6.67 2.03602627 2.59607321 2.0647311 2.53197594 3.70988174 1.16649089 2.44488968 5.84157236 1.298227665 
 
 
31 32 33 34 35 36 37 38 39 
0.052 4.88905973 4.02691269 6.73959612 4.94808187 3.98285939 3.86901518 3.36019833 5.24880273 3.865148102 
0.104 4.91848226 4.27164928 6.67921189 4.8598132 4.34923514 3.6729678 3.33675908 4.81145725 4.006828377 
0.208 4.7540648 3.87676096 5.56779998 4.78267494 3.66196541 3.51837769 3.22199264 4.88905973 3.92748786 
0.416 4.27592306 3.8884087 5.48490624 4.7970445 3.61828443 3.36356021 3.14558537 5.0178422 4.16618188 
0.833 4.85010328 3.78482632 5.55112161 4.98283995 3.68768909 2.95648186 3.39396889 4.7970445 4.059257195 
1.6 4.38855493 3.64370128 5.40865258 5.58452846 4.24609612 3.1298967 3.68400325 4.18706495 4.595143569 
3.3 2.78709546 4.00282355 4.20384675 5.65194651 3.80379784 2.30942829 5.1243311 3.78482632 6.404494439 
6.67 2.16842262 1.84596098 4.73982398 1.47402978 1.84780787 4.89395123 5.24355656 1.42475519 4.022887788 
 
 
 
5 
 
Table of absorbance readings at 590nm for Staphylococcus aureus after adding MTT 
 
[mg ml-1] = Concentration of compound in mg ml-1
 
Ctrl = Control is the reference drug streptomycin 
[mgml-] Compounds  
 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Ctrl 
0.052 1.266 1.303 1.292 1.272 1.385 1.602 1.32 1.397 1.221 1.182 1.224 1.79 1.543 1.367 1.418 1.957 1.477 1.547 0.050 
0.104 1.262 1.281 1.269 1.258 1.387 1.549 1.377 1.417 1.209 1.176 1.225 1.951 1.431 1.445 1.441 1.977 1.568 1.681 0.050 
0.208 1.24 1.288 1.277 1.255 1.391 1.535 1.314 1.469 1.175 1.142 1.171 1.895 1.346 1.477 1.485 1.807 1.530 1.557 0.050 
0.416 1.269 1.245 1.246 1.261 1.425 1.385 1.322 1.522 1.275 1.14 1.219 1.867 1.164 1.452 1.506 1.884 1.584 1.594 0.050 
0.833 1.121 1.296 1.198 1.315 1.401 1.144 1.467 1.609 1.432 1.102 1.217 1.728 1.242 1.604 1.429 1.795 1.509 1.693 0.050 
1.6 1.131 1.234 1.153 1.316 1.400 0.246 1.546 1.613 1.561 1.16 1.168 1.121 1.203 1.636 1.234 1.654 1.588 1.459 0.050 
3.3 0.973 0.971 0.973 1.133 1.078 0.164 1.467 1.542 1.477 0.905 1.112 0.453 0.725 1.228 1.178 1.063 0.466 1.354 0.050 
6.67 0.463 0.314 0.386 0.374 0.954 0.100 1.349 1.304 1.464 0.303 0.363 0.448 0.725 0.278 1.169 0.954 0.089 1.434 0.050 
6 
 
Table of absorbance readings at 590 nm in natural log for Staphylococcus aureus after adding MTT 
 
 
22 23 24 25 26 27 28 29 30 
0.052 3.5466376 3.68032109 3.6400594 3.56798139 3.9948259 4.9629484 3.74342138 4.0430526 3.390576616 
0.104 3.53247939 3.60023816 3.55729349 3.51837769 4.00282355 4.70676107 3.96299479 4.12472768 3.350132844 
0.208 3.45561346 3.62552824 3.58586598 3.50783837 4.01886691 4.64132553 3.7210281 4.34488808 3.238142944 
0.416 3.55729349 3.4729348 3.47640947 3.52894867 4.15785784 3.9948259 3.75091571 4.5813788 3.57870141 
0.833 3.06792059 3.6546488 3.31348332 3.72475099 4.0592572 3.13930049 4.33620699 4.99781092 4.187064953 
1.6 3.0987537 3.43494186 3.16768171 3.7284776 4.05519997 1.27889957 4.69266194 5.0178422 4.763582447 
3.3 2.64587018 2.64058372 2.64587018 3.10495741 2.93879608 1.17821432 4.33620699 4.67392879 4.379786592 
6.67 1.58883334 1.36888974 1.47108467 1.45353715 2.59607321 1.10517092 3.85357003 3.68400325 4.32321786 
 
 
31 32 33 34 35 36 37 38 39 
0.052 3.26088946 3.40076362 5.98945247 4.67860505 3.92356233 4.12885447 7.078061 4.37978659 4.697356952 
0.104 3.24138271 3.40416608 7.03571978 4.18287998 4.24185214 4.22491862 7.22104732 4.7970445 5.370924211 
0.208 3.13302816 3.22521624 6.6525484 3.84202665 4.37978659 4.41496541 6.09214356 4.61817682 4.744566175 
0.416 3.12676837 3.38380224 6.46886068 3.20271856 4.27164928 4.50866004 6.57977138 4.87441453 4.923403206 
0.833 3.01018037 3.3770414 5.62938387 3.46253161 4.97288423 4.17452258 6.01947472 4.52220633 5.435763559 
1.6 3.18993328 3.21555509 3.06792059 3.33009223 5.13459002 3.43494186 5.22784946 4.89395123 4.301655721 
3.3 2.47193192 3.04043318 1.57302419 2.0647311 3.41439392 3.24787196 2.8950431 1.593607 3.872886133 
6.67 1.35391446 1.43763586 1.5651787 2.0647311 1.3204862 3.21877226 2.59607321 1.09308066 4.195447463 
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Table of absorbance readings in 590 nm for Proteus hauseri after adding MTT 
 
[mg ml-
1] 
Compounds  
 22 23 24 25 26 27 28 29 30 31 32 33 34 35    36 37 38 39 Ctrl 
6.67 0.463 0.314 0.386 0.374 0.954 0.455 1.851 1.597 1.464 1.514 1.15 1.207 1.126 1.629 1.611 1.717 1.658 1.357 0.050 
3.3 0.973 0.971 0.973 1.133 1.078 0.163 1.741 1.542 1.477 1.715 1.215 1.209 1.132 1.602 1.660 1.750 1.599 1.391 0.050 
1.6 0.172 1.234 1.153 1.316 1.400 0.198 1.832 1.782 1.561 1.712 1.206 1.174 1.116 1.583 1.625 1.717 1.615 1.388 0.050 
0.833 0.121 1.296 1.198 1.315 1.401 0.193 1.67 1.609 1.432 1.644 1.223 1.214 1.155 1.562 1.562 1.772 1.555 1.329 0.050 
0.416 0.269 1.245 1.246 1.261 1.425 0.189 1.522 1.522 1.275 1.544 1.183 1.219 1.194 1.503 1.438 1.714 1.216 1.338 0.050 
0.208 1.240 1.288 1.277 1.255 1.391 0.437 1.413 1.469 1.175 1.519 1.149 1.173 1.215 1.454 1.399 1.648 1.171 1.412 0.050 
0.104 1.262 1.281 1.269 1.258 1.387 1.259 1.377 1.417 1.209 1.345 1.132 1.451 0.987 1.131 1.388 1.436 0.945 1.433 0.050 
0.052 1.266 1.303 1.292 1.272 1.385 1.287 1.320 1.397 1.221 0.894 0.351 0.683 0.789 1.114 1.201 1.333 0.879 0.929 0.050 
 
[mg ml-1] = Concentration of compound in mg ml-1
 
Ctrl = Control is the reference drug streptomycin 
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Table of absorbance readings at 590 nm in natural log for Proteus hauseri after adding MTT 
 
 
22 23 24 25 26 27 28 29 30 
6.67 1.58883334 1.36888974 1.47108467 1.45353715 2.59607321 1.57617338 6.36618252 4.93819559 4.32321786 
3.3 2.64587018 2.64058372 2.64587018 3.10495741 2.93879608 1.17703669 5.70304362 4.67392879 4.379786592 
1.6 1.18767783 3.43494186 3.16768171 3.7284776 4.05519997 1.21896239 6.24636691 5.941728 4.763582447 
0.833 1.12862491 3.6546488 3.31348332 3.72475099 4.0592572 1.21288279 5.3121678 4.99781092 4.187064953 
0.416 1.30865514 3.4729348 3.47640947 3.52894867 4.15785784 1.20804095 4.5813788 4.5813788 3.57870141 
0.208 3.45561346 3.62552824 3.58586598 3.50783837 4.01886691 1.54805608 4.10826172 4.34488808 3.238142944 
0.104 3.53247939 3.60023816 3.55729349 3.51837769 4.00282355 3.52189783 3.96299479 4.12472768 3.350132844 
0.052 3.5466376 3.68032109 3.6400594 3.56798139 3.9948259 3.62190453 3.74342138 4.0430526 3.390576616 
 
 
31 32 33 34 35 36 37 38 39 
6.67 4.54487398 3.15819291 3.343439274 3.083298606 5.098773395 5.007816541 5.567799984 5.248802734 3.884522237 
3.3 5.556675512 3.370294064 3.350132844 3.101854009 4.962948402 5.259310844 5.754602676 4.948081868 4.018866911 
1.6 5.540030466 3.340097506 3.234906419 3.052619273 4.869542548 5.078419037 5.567799984 5.027887923 4.006828377 
0.833 5.175831487 3.397364554 3.366925455 3.174023418 4.768348412 4.768348412 5.882606818 4.735086525 3.777264234 
0.416 4.683285999 3.264151985 3.383802239 3.300255864 4.495154325 4.212262861 5.551121614 3.373666044 3.811413051 
0.208 4.567655255 3.155036295 3.23167313 3.370294064 4.280201124 4.051146794 5.196576275 3.225216243 4.104155512 
0.104 3.838186541 3.101854009 4.267379762 2.683172867 3.098753705 4.006828377 4.203846754 2.572813379 4.191254112 
0.052 2.444889677 1.420487326 1.979808257 2.201194131 3.046520135 3.3234387 3.792403549 2.408490012 2.531975935 
 
